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CHAPTER 1 
INTRODUCTION 
INTRODUCTION 
Rheumatoid arthritis is a systemic illness with usually poly-
arthritis as the most important manifestation (1). The aetio-
logy of rheumatoid arthritis is unknown; a recent hypothesis 
is that, in a person with a distinct genetic make-up, some 
initiating agent not only leads to an immune response and in-
flammation but also to continued disease activity ( 2 , 3 , 4 ) . 
The natural history of rheumatoid arthritis is variable and 
capricious, ranging from episodes of polyarthritis alternated 
by spontaneous remissions to a rapidly progressive arthritis, 
sometimes with widespread systemic features ( 1 ) . This stresses 
the need to evaluate therapeutic approaches on the basis of a 
controlled clinical study (5). 
Many treatment modalities are involved in the management of 
rheumatoid arthritis, one of these being pharmacotherapy (6). 
The choice, which drug to be given at what time, is made de-
pending on several factors: 1. how firm is the diagnosis?; 
2. what is the extent and the intensity of the rheumatoid ar-
thritis?; 3. is the patient's pain caused by arthritis or des-
tructive lesions mainly?. The drugs used in the treatment of 
rheumatoid arthritis can be arranged under three headings. 
Phase I drugs: non-steroidal anti-inf1ammatory drugs (NSAID): 
they give relief of pain and some reduction of the inflammation, 
with a rather prompt (hours or days) onset of therapeutic acti-
vity. They do not essentially influence the natural history of 
the disease ( 7 , 8 ) . 
Phase II drugs: remission-inducing drugs, also called slow-
acting antirheumatic drugs or disease-modifying antirheumatic 
drugs: hydroxychloroquine, gold compounds and D-penici11 ami ne. 
In contrast with phase I drugs one may not expect therapeutic 
effect of these drugs until after 8-12 weeks of treatment; 
apart from this later onset of action they possess the potency 
to induce a remission. However, the risks in terms of toxicity 
are much greater than those with phase I drugs (9,10). 
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Phase III drugs: immunoregulatory agents: azathioprine, cyclo-
phosphamide, systemic corticosteroids and levamisole. They 
are generally more toxic than the phase II drugs (9,10). 
Phase I drugs are used in the treatment of rheumatoid arthritis, 
alone or in combination with phase II or III drugs. If the 
pain can be ascribed to destructive lesions, then treatment 
with simple analgesics (acetaminophen and glafenine) can be 
considered. Phase II drugs are generally reserved for patients 
who fail to respond to NSAID alone, with a proven diagnosis. 
Phase III drugs are given to patients refractory to the pre-
viously mentioned drugs. 
Among the most widely and intensively studied drugs in the 
treatment of rheumatoid arthritis are the gold salts, auro-
thioglucose and aurothiomalate, which are intramuscularly ad-
ministered (11). The exact mechanism by which gold compounds 
suppress chronic inflammation is still unknown. Since gold 
compounds were introduced in the treatment of rheumatoid ar-
thritis in the beginning of this century because of their 
antimicrobial qualities, many other possible actions have been 
demonstrated (12,13). In the presence of gold compounds, lym-
phocytes do not respond appropriately (14), macrophages do not 
phagocytose efficiently ( 1 5 ) , and multiple isolated enzyme 
systems are suppressed (16). Several controlled studies have 
shown that gold compounds are effective in the treatment of 
rheumatoid arthritis (17-22). For this reason they are still 
used in rheumatoid arthritis despite the high frequency of 
adverse reactions. The uncomfortable mode of administration 
has prompted a search for an orally absorbable gold compound 
which should be as effective as the intramuscularly adminis-
tered gold compounds. Auranofin (S-triethylphosphine gold 2,3, 
4,6-tetra-0-acetyl-1-thio-B-D-glucopyranoside) is orally ab-
sorbed. Several preliminary studies, the first dating from 
1976, have reported that this drug has antirheumatic activity 
(23). We started a formal clinical trial comparing the efficacy 
and safety of auranofin with aurothioglucose in October 1980. 
Patients had given informed consent for this study; the Hospi-
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pital Ethics Committee had given approval to the protocol). 
To score therapeutic response we used a nodification of an 
index of disease activity adapted from Mallya (24). The re­
sults of this single-blind study are presented in chapter 
2 of this thesis. Some of the characteristics of auranofin 
and aurothioglucose are given in table I; the structural formu­
lae of the two mentioned gold compounds are given in figure 1. 
ТаЬЪе I. Characteristics of auranofin and aurothioglucose 
Physico-chemical properties 
lipid sol ubi 1 i ty 
water sol ubi 1 i ty 
monomer iс 
polymeric 
Pharmacokinetic properties 
oral absorbation 
effective route 
peak serum level 
serum protein binding 
erythrocyte binding 
serum t ¿ 
route of elimination 
dosing interval 
Site of action 
Clinical efficacy 
classification of 
antirheumatic activity 
Toxicity 
Legal status 
auranofin 
+ 
-
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-
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oral 
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17 days 
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dermal 
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36 
ko 
39 
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Figure 1. Structural formulae of aurothloglucose and auranofin. 
As mentioned in the introductory remarks, some evidence 
suggests that the genetic make-up of a patient may influence 
the actual acquisition of rheumatoid arthritis (2,25,26). The 
patient's genetic disposition is probably also of importance 
for the extent and activity of the acquired disease: corre­
lations were found between HLA-DR antigens and titre of rheu­
matoid factor (27), progress of rheumatoid arthritis and prog­
nosis of disease (25). No association has so far been found 
between HLA antigens and the therapeutic response to drugs; 
some investigators found associations between HLA-DR antigens 
and toxic reactions to medication (25,26). In the context of 
the clinical trial described, we studied possible associations 
between HLA-antigens and therapeutic response to either aura­
nofin or aurothioglucose, and also correlations between HLA-
antigens and the development of toxic reactions to either 
auranofin or aurothioglucose (chapter 3 ) . 
It has been suggested that the toxic as well as the therapeu­
tic mechanisms of gold action are immune-mediated (28,29,30). 
Several studies have shown a decline in immunoglobulin levels 
during chrysotherapy, and there are contradictory reports as 
to whether or not responders and non-responders show different 
declines in immunoglobulin levels (29,30). With regard to im-
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munoglobuli η levels no differences have so far been reported 
between toxic and non-toxic patients. At regular intervals we 
determined the immunoglobulin levels in our study population 
in order to detect differences between toxic and non-toxic 
patients. Results of these determinations are described in 
chapter 4 of this thesis. Drug-induced IgA deficiencies have 
been described for D-penici 11 amine and aurothiornai ate (31,32). 
In chapter 5 we describe a patient who developed selective IgA 
deficiency during treatment with aurothioglucose. We have 
started attempts to identify the possible pathogenetic mecha­
nism of this adverse reaction. 
The toxicity profile of the orally absorbable gold compound 
is different from that of the intramuscularly administered gold 
compounds. A change in bowel habits is the most frequent ad­
verse reaction to the orally absorbable gold compound. The 
clinical characteristics and the pathogenetic mechanism of 
this adverse reaction were unknown, and this prompted us to 
investigate them in our study population. We describe our 
findings in chapter 6 of this thesis. 
Many attempts have been made to find correlations between the 
serum gold level and either efficacy or toxicity of gold com­
pounds. Although most investigators agree that such an asso­
ciation does not exist (33), some keep claiming the contrary 
(34). Findings on serum gold levels in auranofin- and aurothio­
gl ucose-treated patients are presented in chapter 7 of this 
thesi s. 
In 1980 two articles were published about an association be­
tween the degree of gold binding to the erythrocytes and the 
occurrence of adverse reactions (35,36). These results were 
also contradictory. Since different methods of determining 
the amount of cell-bound gold were used, we compared these 
methods. Results are described in chapter 8. 
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CHAPTER 2 
A SINGLE BLIND COMPARATIVE STUDY OF AURANOFIN AND AUROTHIOGLU-
COSE IN PATIENTS WITH RHEUMATOID ARTHRITIS 
PLCM VAN RIEL, LBA VAN DE PUTTE, FWJ GRIBNAU, KD MACRAE, 
DJAM DE ROOIJ 
Accepted for publication in: 
Proceedings of the International Auranofin Symposium, Amsterdam, 
Excerpta Medica, 1983 
SUMMARY 
Fifty-two patients with rheumatoid arthritis were studied in 
a trial comparing aurothioglucose and auranofin. Up to 40 
patients have been followed up for more than one year. Twenty-
six patients, 13 in each treatment group, dropped out during 
the first year of treatment. The main reason for discontinuing 
treatment with aurothioglucose was adverse reactions and, 
in the auranofin group, lack of efficacy. 
In those patients who continued therapy the results of treat­
ment were comparable; patients on aurothioglucose improved 
slightly more than auranofi η-treated patients, the difference 
being statistically significant on only two occasions. 
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INTRODUCTION 
The statement of Osler: "When the arthritic comes in the front 
door, the doctor wants to go out the back door", could be pro-
perly used to give expression to the restricted amount of 
drugs which are available in the second-line treatment of 
rheumatoid arthritis. This is also accentuated by the high 
percentage of serious adverse reactions occurring, often 
necessitating withdrawal of the drug. Gold is still the drug 
of choice in rheumatoid patients not responsive to NSAID and 
anti-malari al s ( 1 , 2 ) . The high percentage of adverse reactions 
caused by gold salts and the uncomfortable parenteral route 
of administration at weekly or longer intervals has led to the 
search for an orally absorbable and efficacious gold compound. 
Auranofin, an orally absorbable gold compound, developed by 
D.T. Walz et al., proved to be an effective anti-inflammatory 
and immunosuppressive agent in the adjuvant arthritic rat ( 3 ) . 
In 1976, Finkelstein and Berglof demonstrated its effective-
ness in patients with rheumatoid arthritis and it appeared to 
give rise to few adverse reactions (4, 5 ) . This drug may there-
fore afford interesting possibilities in the treatment of 
rheumatoid arthritis. The wide clinical spectrum of rheumatoid 
arthritis and its natural history with the occurrence of exa-
cerbations and spontaneous remission, necessitate controlled 
studies for evaluating therapy. We compared the antirheumatic 
efficacy and safety of auranofin with the conventional intra-
muscularly administered gold compound aurothioglucose in a 
single, i.e. patient, blind controlled trial with one observer. 
MATERIALS AND METHODS 
Patients. Fifty-two patients with classical or definite rheu-
matoid arthritis according to the revised ARA criteria ( 6 ) , 
participated in this study. Patients had an active disease 
defined as having at least three of the following features: 
a. seven or more joints tender or painful on motion. 
b. four or more swollen joints. 
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c. morning stiffness lasting for one hour or longer. 
d. an erythrocyte sedimentation rate (Westergren) greater than 
28 mm/h. 
e. anaemia (Hb <8.7 mmol/1 in males, <7.4 mmol/1 in females). 
Patients previously treated with corticosteroids, D-penicilla-
mine, immunosuppressives or levamisole within 3 months or pa-
renteral gold within 6 months of entry to the trial as well as 
patients with a history of gold toxicity or hypersensitivity 
to heavy metals, were excluded. Concomitant medication with 
NSAID, in a stable dose for one month prior to entry, was 
continued at the start of treatment; no other concomitant 
medication for rheumatoid arthritis was allowed. All patients 
gave their informed consent. 
Drugs and dosing schedules. Patients on auranofin received 6 
mg daily as a single morning dose with breakfast throughout 
the study. Patients on aurothioglucose (Auromyose; 20% oily 
suspension, Noury Pharma, Oss, The Netherlands) started with 
a test dose of 10 mg after which 50 mg weekly was given up to 
a cumulative dose of 1000 mg; thereafter the dose was reduced 
to 50 mg every 2-4 weeks. Placebo tablets containing lactose, 
and placebo injections containing 0.9% sterile saline were 
used as dummy drugs. 
Trial design. The trial was a single-blind double-dummy study 
of auranofin versus aurothioglucose over 12 months. The pa-
tients entered the study during a period of a year, and they 
were allocated either to auranofin or aurothioglucose using 
a blocked randomization orocedure. The patients were studied at 
the outpatient clinic; seven patients (three in the aurothio-
glucose group) were hospitalized during the first period of 
observation due to severe disease activity. Twenty-six patients 
were included in each of the two treatment groups. All patients 
were seen at each visit between 1.00 and 4.00 p.m. by the same 
observer (PvR). The following assessments were recorded fort-
nightly for the first two months and monthly thereafter: 
a. duration of morning stiffness (h) on the day prior to the 
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Visit. 
b. time to onset of fatigue (h) on the day prior to the 
visit. 
c. grip strength (kPa) using a Martin Vigorimeter. 
d. pain assessment by analogue rating on a 10 cm line. 
e. global assessment by analogue rating on a 10 cm line. 
f. number of swollen joints. 
g. number of joints with pain on palpation or passive movement. 
h. physicians assessments of disease activity on a scale of 
1 = none, 2 = mild local, 3 = mild general, 4 = moderate local, 
5 = moderate general, 6 = severe local, 7 = severe general. 
ARA anatomical stage and functional capacity according to 
Steinbrocker (7) were assessed three times during the study. 
Tests for rheumatoid factor were carried out 5 times during 
the study. Additional laboratory tests, undertaken at the 
same time as the clinical assessments, included haemoglobin, 
white blood cell count and differential, platelet count, ESR, 
creatinine, urea, uric acid, alkaline phosphatase, LDH, ALAT 
(SGPT), ASAT (SGOT) and bilirubin. The urine was examined 
microscopically and checked for protein. Blood samples for 
the assay of gold by atomic absorption spectrometry (8) were 
taken at the start of the trial and every two months there-
after. The blood samples were obtained just prior to the in-
jection of aurothioglucose or its placebo. 
Adverse reactions. Side-effects were recorded at each visit, 
reported either spontaneously by the patient or as replies to 
direct questions about:pruritus, skin rash, stomatitis and 
diarrhoea. Patients were withdrawn from the study if the pla-
telet count fell below 100 .OOO/mm^, the white blood cell count 
was less than 3000/mm , the absolute polymorphonuclear count 
fell below 1500/mm^, or proteinuria exceeded 500 mg/24 hrs. 
Patients with a severe generalized dermatitis or stomatitis 
were also withdrawn. Loose stools was defined as a relative 
increase in frequency of bowel movements and in fluidity of 
faeces as compared to the usual bowel habit of the same indi-
vidual ( 9 ) . The reported adverse reactions were tested using 
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an algorithm for assessing the probability of adverse drug 
reactions developed by Naranjo et al.(10). All adverse reac­
tions in this report were classified as "probably" or "definite­
ly" due to the administered drug. All patients who were with­
drawn because of adverse reactions were followed until the 
reactions had cleared. Patients dropping out either because 
of lack of efficacy or side-effects were, if necessary, then 
treated with D-penici11 ami ne. 
Complianoe. Returned drug count was used to measure patient 
compiiance. 
Assessment of response. We used a modification of a recently 
published activity index for rheumatoid arthritis by Mallya 
et al. (11). By using the factor analytic methods, Varimax 
and Quartimax, two sets of five variables were found to mea­
sure the factor "disease activity" most reliably. Providing 
equal weighting for both sets, we did not include pain scale 
and grip strength results in our index, in contrast with 
Mallya et al. The four components used in our index were: 
duration of morning stiffness, total number of tender joints, 
haemoglobin and erythrocyte sedimentation rate (ESR). The 
gradings for these are shown in table I. Dividing the total 
of all grades by four gave a mean value which we used as an 
index of disease activity (IDA). The results are expressed as 
•Table I. Grading of clinical findings. 
Grade morning stiffness number of Hb(mmol/l) ESR(mm/h) 
fmin) tender joints tf g 
«2 »8.7 ЪТЛ 0-20 
3-7 8.1-8.6 6.9-7.3 21-ί»5 
8-17 6.2-8.0 5.3-6.8 46-80 
$18 ^6.1 ^5.2 ¿81 
1 
2 
3 
k 
<10 
10-30 
31-120 
>120 
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Table II. IDA correlated with each of its components. 
IDA r 
range 
ESR 
0.59 
0.51-0.70 
Hb 
0.53 
0.32-0.64 
MS 
0.15-0.52 
No. of tender 
joints 
O.itS 
0.27-0.63 
the percentage improvement from baseline (PIDA) in order to 
correct for initial differences between the two treatment groups. 
As shown in table II each of the four components of the IDA 
were equally weighed in the index. 
Statistical analysis. The t-test for independent groups with 
the pooled variance formula was used for assessment of statis­
tical significance of differences between the treatments. Ρ 
values of <0.05 were considered to be statistically signifi­
cant. Pearson's correlation coefficient was used to correlate 
the results of morning stiffness, number of tender joints, ESR 
and haemoglobin with the index of disease activity. 
RESULTS 
Fifty-two patients equally divided between the two treatment 
groups entered the study. The groups were comparable for most 
of the initial clinical and laboratory assessments, the only 
differences being that patients in the aurothioglucose group 
had a longer disease duration and had been more commonly 
treated in the past with hydroxychloroquine compared with the 
patients in the auranofin group (table III). Until now 40 pa­
tients have been followed up for at least one year. Twenty-six 
patients (50%) were withdrawn during the course of the study. 
Thirteen patients were withdrawn for adverse reactions, 11 of 
whom were in the aurothioglucose group. Eleven patients were 
withdrawn due to lack of efficacy, 10 of whom were in the au­
ranofin group. One patient in each treatment group was with­
drawn for reasons unrelated to the treatment. 
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Table ITI. Clinical characteristics of the patients. 
au ranof ΐ η au rot h i og1ucose 
Total number of patients 
Sex distribution 
fema1 e 
ma 1 e 
Age distribution (yr) 
mean 
SD 
range 
Seropos i t i ve 
ESR (mm/h) 
mean 
SD 
range 
Hb (mmol/l) 
mean 
SD 
range 
D i sease duration (yr) 
mean 
SD 
range 
Previous therapy 
gold 
hydroxychloroquine 
ARA anatomical class 
1 
1 1 
1 1 1 
mean 
Steinbrocker functional class 
1 
1 1 
1 1 1 
mean 
Index of disease activity 
mean 
SD 
range 
HLA haplotype 
DR-Ί 
DR-3 
26 
17 
9 
<.9 
13 
27-69 
22 
58 
36 
15-1Ί7 
7.6 
1.0 
5.6-9.3 
2.5 
3.1 
0.3-1 ι.β 
1 
8 
8 
15 
3 
1.8 
0 
16 
10 
2.Ί 
2.5 
0.5 
1 .5-3.8 
17 
3 
26 
21 
5 
56 
9 
ltl-69 
22 
51 
33 
8-HO 
7.6 
0.9 
5.5-10.3 
5.1 
6.9 
0.3-33.3 
2 
20 
Ц 
19 
3 
2.0 
1 
16 
9 
2.3 
2Π 
0.5 
1.5-3.9 
16 
6 
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Figure 1. 
Drop-out rales ¡η patients treated 
w i t h auranofin and aurothioglucose 
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Tobte IV. L i s t o f adverse reac t i ons and w i t hd rawa l s . 
Adverse drug reaction 
dermati tis 
loose stools 
stornati ti s 
proteinuria 
polyneuropathy 
IgA deficiency 
Total adverse reactions 
Lack of efficacy 
Not drug related 
intercurrent illness 
lack of cooperation 
TOTAL 
no 
Auro 
. of 
patients 
15 
1 
2 
1 
1 
1 
21 
1 
1 
0 
23 
111 ioq 
no 
wi' 
lucose 
. of 
thdrawals 
6 
0 
1 
1 
1 
0 
11 
1 
1 
0 
13 
no 
Aurano 
. of 
patients 
3 
11 
0 
0 
0 
0 
1Í» 
10 
0 
1 
25 
fin 
no 
wi 
. of 
thdrawals 
1 
1 
0 
0 
0 
0 
2 
10 
0 
1 
13 
Some p a t i e n t s exper ienced more than one adverse r e a c t i o n a t the same t i m e . 
The average compliance to p resc r i p t i on was 98.5% (expressed as 
the average number of t ab le t s taken per month d iv ided by ave-
rage number of tab le ts described per month times 100%). 
The commonest s i de -e f f ec t in the auranof in pa t ien ts was loose 
s t o o l s ; 11 pa t ien ts experienced t h i s s i d e - e f f e c t dur ing some 
period of the t r i a l , but only in 1 pa t ien t was i t the reason 
fo r w i thdrawal . Three pat ien ts in the auranof in group had derma-
t i t i s , in one case being a general ized de rmat i t i s unresponsive 
to dose decrement. A f te r withdrawal the de rmat i t i s disappeared 
w i th in two weeks. Rechallenge wi th auranof in caused a recur-
rence of the d e r m a t i t i s . The commonest s i d e - e f f e c t in the au-
rothioglucose pat ients was d e r m a t i t i s , 8 pa t ien ts being w i t h -
drawn fo r t h i s reason. The dermat i t i s pers is ted fo r several 
months a f t e r withdrawal of t reatment. Reasons fo r drop-out and 
the drop-out rates fo r both treatment groups are shown in tab le 
IV and f i gu re 1 respec t i ve l y . 
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Tobte V. Changes in rheumatoid factor for both treatment groups 
change in tube dilution 
change of less than 2 
decrease of $2 
increase of $2 
auranofin 
17* 
5 
1» 
aurothioglucose 
19 
7 
1 
» number of patients 
For evaluating therapeutic response we compared the percentual 
changes in IDA from baseline (PIDA) for all patients in both 
treatment groups up to the 6th month of treatment. Improvement 
was seen for both therapies; at month 4, the aurothioglucose 
treated patients were significantly more improved than the 
auranofin treated patients (p < 0 . 0 5 ) , as shown in figure 2. 
We also compared patients in both treatment grouos who completed 
one year treatment. Again, improvement was seen in patients in 
both treatment groups, with significantly more improvement 
for aurothioglucose treated patients at month 9 (p < 0 . 0 5 ) , as 
shown in figure 3. Patients withdrawn in the auranofin treated 
group did not show any improvement since that was mainly the 
reason for drop-out. When switched to D-penici 11 ami ne a rapid 
onset of response was seen, leading to an improvement in IDA 
of about 35% at month 12. The drop-outs in the aurothioglu-
cose group, mainly withdrawn because of side-effects, improved 
up to month 12 without other therapy (figure 4 ) . 
Changes in rheumatoid factor for both treatment groups are 
given in table V. Three patients in the aurothioglucose group 
and none in the auranofin group became seronegative. Sixteen 
patients in the aurothioglucose group and 13 patients in the 
auranofin group were able to reduce the dose of concomitantly 
administered NSAID. 
DISCUSSION 
Previous studies have demonstrated the superiority of aurano-
fin, in a dose of 6 mg daily, to placebo in the treatment of 
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rheumatoid arthritis (12,13). In the present study we compared 
the efficacy and safety of aurothioglucose and auranofin. High 
numbers of withdrawals from both treatments forced us to sub-
divide the two treatment groups into three populations. The 
number of withdrawals was equal in both treatment groups. The 
reason for withdrawal was mainly lack of efficacy in the aura-
nofin patients and side-effects in the aurothioglucose patients. 
Loose stools was the most frequent adverse reaction in the 
auranofin group, but led to withdrawal of only one patient. 
The commonest side-effect in the aurothioglucose patients was 
dermatitis leading to 8 withdrawals. When the two treatment 
groups as a whole were compared up to the 6th month of therapy, 
the aurothioglucose patients improved slightly more than the 
auranofin patients, reaching a statistically significant level 
only at month 4. The same was seen when all patients treated 
up to 12 months (responders) were compared, a statistically 
significant difference being found only at month 9. Comparison 
of the withdrawn patients showed, as expected, no improvement 
in the auranofin patients; the aurothioglucose patients im-
proved with a statistically significant difference at month 
4. This improvement was sustained until month 12. Auranofin 
patients withdrawn because of lack of efficacy were next 
treated with D-penici 11 amine; after 6 months they had improved 
to the same extent as the aurothiogl ucose treated patients af-
ter one year of treatment. The mean onset of response was 
slightly earlier in the aurothioglucose patients than in the 
auranofin patients (month 3 versus month 4 ) . 
As to the difference in disease duration in the two treatment 
groups, no statistically significant correlations were found 
between the IDA and the duration of disease, so this could 
not explain the difference in response. 
In conclusion, we would say that concerning safety, auranofin 
had far less serious side-effects and if present they cleared 
faster than those associated with aurothioglucose. However, 
concerning efficacy, aurothiogl ucose was more effective than 
auranofin, although the difference only occasionally reached 
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statistical significance. Whether increasing the dose of au-
ranofin in the non-responders will improve the efficacy remains 
a subject for further study. 
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CHAPTER 3 
ASSOCIATION OF HLA ANTIGENS, TOXIC REACTIONS AND THERAPEUTIC 
RESPONSE TO AURANOFIN AND AUROTHIOGLUCOSE IN PATIENTS WITH 
RHEUMATOID ARTHRITIS 
PLCM VAN RIEL, Ρ REEKERS, LBA VAN DE PUTTE, FWJ GRIBNAU 
Accepted for publication in: 
Tissue Antigens 
SUMMARY 
To investigate the possible relation between HLA antigens and 
either favourable clinical response or toxic reaction to two 
different gold compounds: aurothioglucose and auranofin (a 
new orally absorbable gold compound),we studied 50 patients 
with rheumatoid arthritis prospectively. Of the 25 aurothio­
gl ucose-treated patients response to treatment could not be 
evaluated in four patients because of early toxicity. Nine pa­
tients showed an excellent response, while 12 were moderate 
or non-responders. Four of the 9 excellent responders were 
HLA-DR3 positive, but none of the 12 moderate or non-respon­
ders possessed this antigen (p < 0 . 0 2 5 ) . In accordance with 
previous reports HLA-DR3 was found more frequently in patients 
developing toxicity on aurothioglucose than in those who did 
not (RR = 5 . 6 ) . No association was found between HLA antigens 
and favourable clinical response in 25 auranofi η-treated pa­
tients. Two of them showed a severe adverse reaction, neither 
of them being DR3-positi ve. HLA-DR3 positivity is associated 
not only with drug toxicity, but also with excellent responder-
ship to aurothioglucose treatment. 
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INTRODUCTION 
Genetic factors play a role in the pathogenesis of rheumatoid 
arthritis (RA), since HLA-DW4/DR4 has been shown to be signi-
ficantly increased in patients with the latter disease (1). 
Recently studies have been reported on associations between 
HLA antigens and the occurrence of side effects on slow acting 
antirheumatic drugs. HLA-DR3 was found to be increased in RA 
patients with gold- and/or D-penici 11 amine-induced proteinuria 
( 2 ) , dermatitis (3,4) and haematological abnormalities ( 5 ) . 
In addition, HLA-B27 was shown to occur more frequently in RA 
patients with levami sole-induced agranulocytosis ( 6 , 7 ) . Interes-
tingly, no detailed studies have so far been published on a 
possible association between HLA antigens and responsiveness 
to drug treatment in RA, although one congress presentation 
reports on the absence of such an association ( 8 ) . It is con-
ceivable that like studies may have been hampered by difficul-
ties in quantitating clinical response to drug treatment in RA 
patients. In the present study we made an attempt to overcome 
this problem by using a modification of a recently developed 
scoring system (9) for the evaluation of disease activity in 
RA. Using this system we evaluated clinical responses to auro-
thioglucose or auranofin, a new orally absorbable gold com-
pound, in the context of a patient blind study comparing the 
efficacy and safety of these drugs. We studied the possible 
associations between HLA antigens and clinical response and/or 
toxicity in these patients. 
PATIENTS AND METHODS 
Patients. In this study, an intramuscularly administered gold 
compound (aurothioglucose) and an orally absorbable gold com-
pound (auranofin) were compared for efficacy. Fifty Caucasian 
patients with classical or definite rheumatoid arthritis (RA) 
according to the revised ARA criteria ( 1 0 ) , participated the 
study. The patients had active disease, defined as showing 
at least three of the following features: a) seven or more 
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tender joints or joints painful on motion; b) four or more 
swollen joints; c) morning stiffness lasting one hour or 
longer; d) an erythrocyte sedimentation rate (Westergren) 
exceeding 28 mm/h; e) anaemia (Hb <8.7 mmol/1 in males, <7.4 
mmol/1 in females). Twenty-one of the 25 patients of the auro-
thioglucose group were analysed for a correlation between 
HLA-DR phenotype and response to therapy. In four patients, 
treatment had to be stopped within 4 months in view of adverse 
reactions. Two of the 25 patients of the auranofin group could 
not be analysed for response evaluation; one was withdrawn 
within two months of treatment in view of an adverse reaction, 
the other dropped out due to non-compliance after two months 
of treatment. 
Drugs and dosage schedule. Patients on auranofin received 6 mg 
daily as a single morning dose. After a test dose of 10 mg, 
patients on aurothioglucose received 50 mg weekly up to the 
20th week, after which the dose was reduced to 50 mg every 
2-4 weeks. 
Evaluation of response. Clinical and laboratory assessments 
were made before institution of treatment, biweekly during the 
first two months and monthly thereafter. This schedule was 
also maintained if patients were withdrawn because of toxicity, 
until institution of another form of therapy. A modification 
of a recently published activity index for rheumatoid arthritis 
(9) was used for evaluation of response. The four components 
of our index of disease activity (IDA) and its gradings are 
shown in table I. The degree of improvement on therapy in each 
patient was obtained by determining the percentage of improve-
ment from baseline (PIDA). The mean IDA and the mean PIDA were 
calculated for each patient from the assessments of the 4th 
through the 12th month of treatment. Patients withdrawn from 
the study in view of toxicity were included for response éva-
luât! on i f they had been treated with the gold compound for at 
least 4 months. 
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Tobte I. Grading of clinical findings for definition of IDA. 
Grade 
1 
2 
3 
k 
Duration of 
morning stiffness 
(mi n) 
<10 
10-30 
31-120 
>120 
Number of 
tender jo i 
«2 
3-7 
8-17 
»18 
nts 
Hb(mmc 
»8.7 
8.1-8.6 
6.2-8.0 
$6.1 
.1/1) 
»7.Ί 
6.9-7. 
5.3-6. 
$5.2 
.3 
.8 
ESR(mm/h) 
0-20 
21-i(5 
46-80 
»81 
Criteria of response. Evaluation of response was based on the 
degree of improvement in IDA from baseline (PIDA) as well as 
on the degree of disease activity (IDA) attained. The mean 
IDA as well as the mean PIDA were arbitrarily divided into six 
classes (tabi e II). 
Table II. Grading of the mean index of disease activity (IDA) and of the 
mean percentage of improvement in IDA from baseline (PIDA). 
Class IDA P I D A {%) 
1 1-1.5 51-60 
2 1.6-2.0 Ή-50 
3 2.1-2.5 31-^0 
U 2.6-3.0 21-30 
5 3.1-3.5 11-20 
6 3.6-Ί.0 <10 
Patients were considered to have shown an excellent response 
if their mean IDA ánd PIDA, measured over a 8-month period, 
both were in the first three classes. Patients withdrawn due 
to toxicity were considered to have shown an excellent re-
sponse if their mean IDA and mean PIDA, measured over a period 
of at least 3 months,were i η the first three classes. Non-
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responders were patients who either improved less than 10% 
from baseline or deteriorated (class 6 P I D A ) . Moderate respon­
ders were patients not covered by the previous classifications. 
Assessments of adverse reactions. Patients were considered to 
have developed adverse reactions to aurothioglucose or aurano-
fin if any of the following signs were observed: severe pruri­
tus, rash or stomatitis which diminished after stopping treat­
ment; proteinuria exceeding 500 mg/24 h for more than two weeks; 
a fall in platelet count below 100,000/mm 3; white blood cell 
count less than 3000/mm 3 or an absolute polymorphonuclear count 
below ISOO/mm 3. Twenty-five patients in the aurothioglucose 
group and 24 patients in the auranofin group could be analysed 
for adverse reactions. 
HLA t y p i n g . HLA typing was done after a 6-month trial period. 
The results of typing were not known to the observer (PvR) 
until the response classification had been made. For HLA-ABC 
typing, standard NIH-procedures were used. HLA-DR typing was 
done on В cells after enrichment by AET rosetting, using 58 
sera that defined DR1-DRW10 as well as MB and MT specificities. 
A control group consisted of 277 healthy voluntary blood donors 
living in the same region as the patients. 
S t a t i s t i c a l a n a l y s i s . Fisher's exact test for comparison of two 
proportions was used to assess statistical significance of data. 
RESULTS 
Comparison of the two treatment groups. The aurothioglucose-
treated and the auranofi η-treated patients were comparable as 
to age and sex distribution, seropositi vity, disease activity 
and duration of disease. HLA-ABC antigens had a normal fre­
quency distribution in both patient groups. Compared with the 
normal population, HLA-DR4 frequency was found to be increased 
in both aurothioglucose- and auranofi η-treated patients (56% 
and 68% respectively). 
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Table I I I . HLA-DR3 frequency and response to a u r o t h i o g l u c o s e and a u r a n o f i n . 
Response 
excel lent 
moderate/no res ipoi nse 
DR3 
't 
0 
AUROTHIOGLUCOSE 
+ DR3 -
.
 5 
12 
total 
9 
12 
DR3 + 
1 
2 
AURANOFIN 
DR3 -
k 
16 
total 
5 
18 
* ρ <0.025 F i s h e r ' s exact t e s t 
No s t a t i s t i c a l l y s i g n i f i c a n t d i f f e r e n c e s were f o u n d between 
the a u r o t h i o g l u c o s e - t r e a t e d p a t i e n t s , t h e a u r a n o f i n - t r e a t e d 
p a t i e n t s and a group of h e a l t h y c o n t r o l s w i t h r e s p e c t t o t h e 
d i s t r i b u t i o n of the o t h e r HLA-DR a n t i g e n s . 
HLA and response. Twenty-one p a t i e n t s i n t h e a u r o t h i o g l u c o s e 
group were a n a l y s e d f o r a c o r r e l a t i o n between c l i n i c a l c h a r a c ­
t e r i s t i c s , HLA a n t i g e n s and response a f t e r a t l e a s t 4 months 
o f t r e a t m e n t . Nine p a t i e n t s responded e x c e l l e n t l y (mean IDA 
and PIDA both i n the f i r s t t h r e e c l a s s e s , t a b l e I I ) t o t r e a t ­
ment a c c o r d i n g t o our s c o r i n g c r i t e r i a . Seven p a t i e n t s were 
moderate r e s p o n d e r s and 5 were n o n - r e s p o n d e r s . E x c e l l e n t , mo­
d e r a t e and n o n - r e s p o n d e r s were equal i n c l i n i c a l c h a r a c t e r i s ­
t i c s and d i s t r i b u t i o n of HLA-ABC a n t i g e n s . Four o f t h e 9 e x c e l ­
l e n t r e s p o n d e r s were HLA-DR3-posi t i v e , whereas none o f the 12 
moderate or n o n - r e s p o n d e r s was p o s i t i v e f o r HLA-DR3 (p < 0 . 0 2 5 , 
t a b l e I I I ) . Response t o t r e a t m e n t w i t h a u r a n o f i n was r e v i e w e d 
i n 23 p a t i e n t s . Only f i v e p a t i e n t s showed an e x c e l l e n t r e s p o n s e ; 
7 were moderate and 11 were n o n - r e s p o n d e r s . Three p a t i e n t s 
e v e n l y d i s t r i b u t e d over t h e s e 3 g r o u p s , were HLA-DR3-pos i t i ve 
( t a b l e I I I ) . 
HLA and adverse reaction. Four p a t i e n t s had such severe a d ­
verse r e a c t i o n s t h a t t r e a t m e n t w i t h a u r o t h i o g l u c o s e had t o be 
s topped w i t h i n 4 months (3 d e r m a t i t i s , 1 p o l y n e u r o p a t h y ) ; two 
of them were HLA-DR3-posi t i ve. Ten a d d i t i o n a l p a t i e n t s were 
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Table IV. HLA-DR3 frequency and t ox i c reac t i on to au ro th iog lucose . 
DR3 + DR3 - t o t a l 
Toxic p a t i e n t s 
- wi thdrawn <'• nronths 2 2 k 
- wi thdrawn ^k months 3 7 10 
Non- tox ic p a t i e n t s 1 10 11 
wi' thdrawn between 4 and 12 months o f t r e a t m e n t i n view o f se-
vere adverse r e a c t i o n s t o a u r o t h i o g l u c o s e (8 d e r m a t i t i s , 1 
s t o m a t i t i s , 1 p r o t e i n u r i a ) . Three o f them were HLA-DR3-pos i t i ve . 
In the n o n - t o x i c group o f 11 p a t i e n t s , on l y one was DR3-pos i -
t i v e . The d i f f e r e n c e s between the t h r e e groups d i d not a t t a i n 
s t a t i s t i c a l s i g n i f i c a n c e ( t a b l e I V ) . At i n s t i t u t i o n o f t r e a t -
ment the t o x i c and the n o n - t o x i c p a t i e n t s were comparable as 
t o age and sex d i s t r i b u t i o n , s e r o p o s i t i v i t y , d isease d u r a t i o n , 
a c t i v i t y o f d isease and d i s t r i b u t i o n o f HLA-ABC a n t i g e n s . Only 
two p a t i e n t s i n the a u r a n o f i n group showed a severe adverse 
r e a c t i o n , which made i t necessary t o s top t r e a t m e n t . N e i t h e r 
o f them was HLA-DR3-pos i t i ve . 
DISCUSSION 
Our data i n d i c a t e an a s s o c i a t i o n between HLA-DR3 p o s i t i v i t y 
and e x c e l l e n t c l i n i c a l response i n the a u r o t h i o g l u c o s e t r e a t e d 
p a t i e n t s w i t h RA. Th is a s s o c i a t i o n c o u l d not be shown i n the 
a u r a n o f i n t r e a t e d g r o u p , p robab ly because of s m a l l e r numbers 
o f DR3 p o s i t i v e p a t i e n t s and o f e x c e l l e n t r esponde rs . Both pa-
t i e n t groups were comparable i n the f requency o f HLA an t i gens 
and showed an i n c r e a s e d HLA-DR4 f requency as compared to h e a l -
t hy c o n t r o l s , i n accordance w i t h p rev i ous r e p o r t s ( 1 , 3 , 1 1 ) . 
To our knowledge on ly one group has s t u d i e d p o s s i b l e a s s o c i a -
t i o n s between HLA a n t i g e n s and c l i n i c a l response to slow a c t i n g 
a n t i r h e u m a t i c d r u g s , i n t h i s case a u r o t h i o m a l a t e ( 8 ) . These 
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authors were unable to find any association, but excluded pa-
tients with drug-induced toxicity. We consider it justifiable 
to include in the analysis those patients withdrawn from the 
study because of adverse reactions, who had been treated for 
at least four months, since after that time clinical improve-
ment can be attributedto gold therapy. The importance of this is 
illustrated by the fact that four of the patients in the auro-
thioglucose excellent responder group were withdrawn because 
of adverse reactions, occurring after at least four months of 
treatment, two of them being HLA-DR3 positive. 
Several recent studies have shown associations between HLA-DR3 
and gold- and/or D-penicillamine-induced toxicity, including 
proteinuria ( 2 ) , skin rashes (3,4) and haematological abnor-
malities ( 5 ) . In our study 5 of the 6 DR3 positive patients 
in the aurothioglucose treated group, developed toxic reac-
tions, mainly skin rashes, suggesting an association. However, 
numbers were too small to reach statistical significance. 
Another interesting observation is that two out of four pa-
tients with early aurothioglucose-induced toxicity (occurring 
in the first 4 months) were DR-3-posi ti ve, whereas only three out 
of ten late toxicities (after 4 months) were positive for this 
antigen, suggest!ng that DR3-positi ve patients are prone to early 
toxicity. Similar observations have been done in aurothioglu-
cose- or D-penici11amine-induced proteinuria, showing that ear-
ly and heavy proteinuria was more frequent in DR3-positive 
than in DR3-negative patients (12). 
The present data indicate that DR3 positive patients with RA 
may not only be prone to gold-induced toxicity, as has been 
reported earlier (2,3,4), but also to favourable clinical re-
sponse. Our data do not allow conclusions as to whether in the 
DR3-positive group proneness to develop drug toxicity is asso-
ciated with excellent respondership. If this were true, it 
would be worthwhile to treat this group of patients with lower 
doses of gold in an attempt to avoid toxicity and at the same 
time retain excellent respondership. 
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SUMMARY 
Serum immunoglobulin concentrations were measured in 25 pa-
tients with rheumatoid arthritis at month 0,1.3,6 and 12 of 
aurothioglucose treatment. Significant lowering of IgA and IgM 
levels was found at month 3 and thereafter, and of IgG at month 
12 only. When patients who developed drug-induced toxicity at 
any time during treatment (toxic group) were compared with 
those who did not (non-toxic group), serum levels of IgA and 
to a lesser degree of IgG, but not of IgM, were found to be 
significantly lower in the toxic than in the non-toxic group, 
both at the onset and during treatment, except for IgG at month 
12. In addition the decline of serum IgA, but not of IgG and 
IgM, during treatment was greater in the toxic than in the non-
toxic group. When measured at the moment of toxicity, only IgA 
but not IgG and IgM, was significantly lower than in sera of 
patients not toxic at that moment. During treatment 6 patients 
developed serum IgA levels below normal; they all had or de-
veloped severe drug toxicity. The serum IgA concentration in 
patients with rheumatoid arthritis seems to be related to 
whether or not aurothioglucose-induced toxicity occurs. 
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INTRODUCTION 
Since more than 50 years gold salts have been successfully 
used in the treatment of rheumatoid arthritis. Their main dis-
advantage is the frequent occurrence of side effects, which 
often necessitate discontinuation of treatment (1). Mechanisms 
involved in the development of drug toxicity are largely un-
known, although genetic factors have recently been implicated 
for gold-induced proteinuria ( 2 ) , skin rashes (3,4) and throm-
bocytopenia (5). Several observations indicate a role of im-
mune mechanisms in the development of gold-induced toxicity. 
Gold-induced proteinuria was shown to be associated with im-
mune complex glomerulonephritis (6) and drug toxicity is often 
preceded by or associated with peripheral blood eosinophilia 
(7), suggesting a type I hypersensitivity reaction. In addi-
tion it has been suggested that gold-induced dermatitis is 
mediated by type IV hypersensitivity reactions ( 8 ) . 
We report on a prospective study of serum immunoglobulin G, A 
and M in patients with rheumatoid arthritis with and without 
toxic reactions to aurothioglucose during treatment with this 
drug. This study was performed in connection with a clinical 
trial comparing the efficacy and toxicity of aurothioglucose 
and auranofin, a new orally absorbable gold compound (9). Since 
patients treated with auranofin developed toxicities on only 
a few occasions, data on these patients were not suitable for 
the purpose of this study and were therefore excluded. Our 
data suggest that the level of serum IgA in patients with 
rheumatoid arthritis is related to whether ornot aurothioglu-
cose-induced toxicity occurs, toxicity occurring predominantly 
in patients with normal or subnormal IgA levels. 
PATIENTS AND METHODS 
Patients. Twenty-five patients with definite or classical 
rheumatoid arthritis according to the revised American Rheu-
matism Association criteria (10) were treated with aurothio-
glucose in a prospective clinical study. All patients had ac-
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Table I . C l i n i c a l c h a r a c t e r i s t i c s o f a l l p a t i e n t s and o f the t o x i c and 
n o n - t o x i c group at the s t a r t o f t r e a t m e n t . 
a l l p a t i e n t s t o x i c group non-tox ic group 
π = 25 η = l'i η = 11 
Sex distribution 
f erna 1 e 
male 
Age distribution 
range 
mean + SD 
Seropositive 
ESR (mm/h) 
range 
mean + SD 
Hb (mmol/l) 
range 
mean + SD 
Disease duration 
range 
mean + SD 
(У-
(У 
rs) 
rs) 
Serum gold (yg/100 ml) 
range 
mean + SD 
HLA antigen 
DR3 
DR4 
20 
5 
39-69 
56+9 
2 1 " \ 
8-140 
50+33 
5.5-10.3 
7.6+1.0 
0.3+33.3 
5.1+6.8 
145-460 
259+79 
6 
15 
12 
2 
39-68 
55+10 
11 
8-110 
'•з+г? 
5.5-10.3 
7.6+1.2 
0.3+33.3 
k.0+8.5 
145-Зг*8 
279+38 
5 
9 
8 
3 
'»7-69 
55+7 
10 
12-Й0 
5 9+'tO 
5.9-8.4 
7.5+0.7 
0.8+14 
5.6+4.3 
158-460 
241+104 
1 
6 
t i v e d i s e a s e u n r e s p o n s i v e t o n o n - s t e r o i d a l a n t i - i n f l a m m a t o r y 
drugs (NSAID) and a n t i m a l a r i a l a g e n t s . C l i n i c a l c h a r a c t e r i s ­
t i c s o f t h e p a t i e n t s are g i v e n i n t a b l e I . Systemic c o r t i c o ­
s t e r o i d s , D - p e n i c i 11 ami ne , immunosuppressive drugs or l e v a m i -
s o l e had n o t been a d m i n i s t e r e d w i t h i n 3 months p r i o r t o i n ­
c l u s i o n i n t h e s t u d y . 
Drug regimen. A f t e r a t e s t dose o f 10 mg, 50 mg a u r o t h i o g l u -
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cose weekly was given Intramuscularly during 20 weeks. The 
dose was then reduced to 50 mg every 2 weeks, up to a cumula-
tive dose of 1500 mg; thereafter 50 mg was given every three 
weeks to the end of the study. Only concomitant medication 
with NSAID was allowed during the study. Adverse reactions 
were searched for at each aurothioglucose injection, and in-
cluded any of the following signs or symptoms, if reversible 
after stopping aurothioglucose treatment: severe pruritus, 
rash or stomatitis, proteinuria exceeding 500 mg/24 h for more 
than two weeks; a fall in platelet count below 100,000/mm3, 
white blood cell count below 3000/mm 3, or an absolute polymor-
phonuclear count below 1500/mm3. Thirteen patients were with-
drawn during the first year of treatment in view of generalized 
dermatitis (one patient had proteinuria at the same time), and 
one in view of polyneuropathy. These 14 patients made up the 
toxic group. Eleven patients without or with minimal local 
dermatitis not necessitating discontinuation of treatment in 
the course of one year formed the non-toxic group. 
No differences in clinical characteristics were found between 
the toxic and the non-toxic group; in accordance with the li-
terature (3) the HLA-DR3 frequency was increased in the toxic 
group as compared with the non-toxic group (table I ) . 
Immunoglobulin assay. Immunoglobulin levels were determined 
at the start of the trial and 1,3,6 and 12 months thereafter 
by the radial immunodiffusion method of Mancini (11) using 
standard commercially obtained immunodiffusion plates and 
standards (Behring Werke, Marburg, W-Germany). Normal serum 
immunoglobulin concentrations are (mean + S D ) : IgA 2.0 + 0.6 
g/1 (119 + 36 I.U./ml), Igm 1.1 + 0.4 g/1 (127 + 46 I.U./ml) 
and IgG 12.5 + 2.1 g/1 (144 + 24 I.U./ml). 
statist-iaal analysis. A paired variate t-test was used to de-
termine the statistical significance of the changes in immuno-
globulin levels before and during gold treatment. Student's 
t-test for independent groups was used to assess the statisti-
cal significance of differences between toxic and non-toxic 
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patients. 
RESULTS 
Serum immunoglobulin levels in the total group of patients be-
fore and during treatment with aurothioglucose are shown in 
table II. Differences between baseline and serial values were 
analysed by a paired variate t-test. Statistically significant 
differences were found for IgA and IgM levels at month 3 and 
thereafter and for IgG at month 12. Comparison of the immuno-
globulin levels of the toxic and the non-toxic group revealed 
statistically significantly lower serum levels of IgA and to 
a lesser degree of IgG both at the onset and during treatment, 
except for IgG at month 12 (table I I ) . However, no significant 
differences in IgM level were seen. For IgG the decline in the 
toxic group was comparable with that in the non-toxic group. 
For IgA, however, the decline was significantly greater in the 
toxic than in the non-toxic group (p <0.02, at month 6 ) . We 
also compared the serum immunoglobulin levels at month 6 and 
12 in patients with an adverse reaction at that time with 
those in patients without an adverse reaction. Significantly 
lower IgA levels were found in the patients with an adverse 
reaction, while no statistically significant differences were 
found in IgG and IgM levels (table I I I ) . Six patients, all 
belonging to the toxic group, developed IgA levels below the 
normal range during treatment. The adverse reaction appeared 
at the same time as or after the serum IgA level became sub-
normal. Three toxic patients with subnormal serum IgA levels 
had subnormal IgM levels at the same time. None of the other 
patients developed subnormal IgM levels during treatment, and 
subnormal IgG levels were never found. 
DISCUSSION 
Adverse reactions remain the major limiting factor of gold 
therapy for rheumatoid arthritis. The present data indicate 
that serum IgA levels in these patients are somehow related 
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Table II. Serum immunoglobulin levels in the total group of aurothioqlucose-treated patients and in the toxic and non-toxic group 
month 
0 
1 
3 
6 
12 
total group0 
3.32+1.18 
(25) 
3.26+1.13 
(25) 
2.7Ί+1.33+ 
(2<0 
2.66+1.2')++ 
(20) 
l.kW.lb*** 
(12) 
IgA» 
toxic group 
2.97+1.16 
(1*) 
2.77+0.97 
ΟΌ 
2.14+1.35 
(13) 
1 .54+1.13 
(10) 
1.07+0.39 
d) 
P« 
value 
<0.02 
<0.01 
<0.01 
<o.oi 
<0.01 
non-toxic 
group 
4.62+1.88 
(11) 
4.70+1.89 
(11) 
4.20+1.90 
(11) 
4.05+1.89 
(10) 
3.50+1.62 
(8) 
total group 
17.59+5.49 
(25) 
17.89+7.41 
(25) 
17.73+5.47 
(24) 
16.73+4.65 
(20) 
14.17+3.37+ 
(12) 
IgG 
toxic group 
15.88+4.82 
(14) 
15.45+6.54 
(14) 
15.39+4.75 
(13) 
14.73+5.01 
(10) 
11.46+3.87 
(4) 
P* 
val ue 
<0.05 
<0.01 
<0.01 
<0.05 
>0.05 
non-toxic 
group 
21.67+6.83 
(11) 
22.81+5.21 
(11) 
21.21+5.21 
(11) 
19.66+4.07 
(10) 
15.97+2.26 
(8) 
total group 
1.34+0.58 
(25) 
1.39+0.59 
(25) 
1.l4+0.55+ 
(24) 
1.17+0.51+ 
(20) 
1.09+0.4l + + + 
(12) 
IgM 
toxic group 
1.41+0.55 
(14) 
1.47+0.68 
(14) 
I.O2+O.54 
(13) 
Ο.96+Ο.52 
(10) 
1.00+0.29 
(4) 
P* 
value 
>0.05 
>0.5 
>0.1 
>0.1 
>0.5 
non-toxic 
group 
I.52+O.69 
(ID 
1.35+0.46 
(11) 
1.33+0.52 
(11) 
1.25+0.41 
(10) 
І.ІЗ+О.47 
(8) 
• Serum immunoglobulin at month 1,3.6 and 12 was compared with that of month 0 by a paired variate t-test; + » ρ <0,05; ++ - ρ <0.01; +++ = ρ <0.001. 
о Mean +^  SD; numbers in parentheses indicate number of patients. 
» Student's t-test for independent groups, i.e. the toxic and non-toxic group. 
LH 
σ\ Table III. Serum ¡mmunoglubul¡π concentrations at month 6 and 12 of treatment in patients with and without 
an adverse reaction at that moment. 
month 
6 
12 
adverse 
reaction 
present 
1.67+0.93 
d) 
1.07+0.39 
W 
lgA+ 
p* 
value 
<0.05 
<0.01 
adverse 
reaction 
absent 
3.28+2.00 
(16) 
3.50+1.62 
(8) 
adverse 
reaction 
present 
15.67+5.20 
(Ί) 
11.^6+3.87 
(*) 
IgG 
P* 
val ue 
>0.5 
>0.05 
adverse 
reaction 
absent 
17.89+5.20 
(16) 
15.97+2.26 
(8) 
adverse 
reaction 
present 
1.11+0.7*» 
W 
1.00+0.29 
w 
IgM 
P* 
val ue 
>0.5 
>0.5 
adverse 
reaction 
absent 
1.15+0.Ή 
(16) 
І.ІЗ+О.47 
(8) 
+ Mean + SD; numbers in parentheses indicate number of patients. 
« Student's t-test for independent groups. 
to whether or not drug toxicity occurs. Comparison of patients 
who developed toxicity at any time during aurothioglucose 
treatment (toxic group) with those who did not (non-toxic 
group) indicated a lower level of IgA in the former group at 
all measurements. In addition, the decline in IgA during treat­
ment was greater in the toxic than in the non-toxic group. 
Of special interest was the observation that all patients who 
developed subnormal IgA levels during treatment were or be­
came toxic later on. 
The relationship between (relatively) low IgA levels and gold 
toxicity is obscure. The number of IgA measurements in our 
study is too small to warrant firm conclusions about a precise 
time relationship between a decline in serum IgA and the de­
velopment of toxicity. However, of the б patients with definite­
ly subnormal IgA levels, 3 already had low IgA levels before 
toxicity developed, whereas the reverse was not observed in 
this study. This fact, together with the observation that the 
toxic group showed lower IgA levels from the start, i.e. be­
fore toxicity developed, suggests that a decline in serum IgA 
at least may facilitate adverse reactions rather than being 
an expression of drug toxicity itself. If this statement is 
correct, then IgA may act as a blocking factor with respect 
to the developement of gold-induced toxicity or hypersensi­
tivity. A decrease in blocking factor may then facilitate 
development of toxicity or hypersensitivity. In this respect 
it may be relevant that a qualitative defect in IgA production 
in patients with atopic allergy is associated with overstimu­
lation of IgE production (12). A blocking action of IgA could 
also explain the fact that, at resumption of gold therapy af­
ter toxicity has disappeared, toxicity generally does not re­
appear as quickly as might be expected in the case of mere 
hypersensitivity. The explanation may be that, after stopping 
gold therapy, IgA levels increase, as we have observed (data 
not s h o w n ) , and thus form a new blocking barrier. 
Monitoring of gold-induced toxicity at this time depends on 
regular clinical evaluation, haematol ogical screening and 
urinalysis. Prediction of gold toxicity at the present state 
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of the art remains virtually impossible. Monitoring of serum-
or cell-bound gold concentrations has been disappointing in 
this respect (13,14,15). Peripheral blood eosinophilia some-
times precedes toxicity, but this remains unreliable (16). The 
association of drug toxicity and certain HLA antigens (2,3,4,5] 
points to a high-risk group with respect to toxicity but is of 
little practical value for the individual patient. The present 
data have to be extended by further studies before definite 
conclusions can be drawn about their value in predicting toxi-
city. Our data suggest, however, that patients with subnormal 
serum IgA are at particular risk and may be future candidates 
for drug dose reduction once IgA becomes subnormal. 
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CHAPTER 5 
IgA DEFICIENCY DURING AUROTHIOGLUCOSE TREATMENT 
PLCM VAN RIEL, LBA VAN DE PUTTE, FWJ GRIBNAU, RMW DE WAAL 
INTRODUCTION 
Selective IgA deficiency is the most common permanent primary 
immune deficiency, estimated to occur in the normal population 
at a rate of one in 500 to 700. Drug-induced selective IgA 
deficiency has been described for Phenytoin ( 1 , 2 ) , D-penicil-
lamine (3,4) and aurothiornai ate (5). This report discusses 
IgA deficiency developing during treatment with aurothioglu-
cose of a patient with seronegative rheumatoid arthritis. 
Immunological data would suggest a defect in IgA secretion 
rather than in manufacturing by plasma cells. 
CASE REPORT 
The patient was a 43-year-old woman, with a 15 year history 
of polyarthritis, who was seen at the out-patient clinic with 
signs of exacerbation. She had previously been treated with 
hydroxychloroquine and non-steroidal anti-inflammatory drugs. 
Physical examination revealed signs of active polyarthritis 
without extra-articular manifestations. Laboratory data were 
as follows: ESR 12 mm after one hour, haemoglobin 7.7 mmol/l, 
normal peripheral blood, leucocytes, differential count and 
hepatic and renal function tests. Serum immunoglobulins: 
IgA 2.29 g/1, IgG 12.45 g/1 and IgM 0.93 g/1 (normal values 
for IgA, IgG and IgM are (mean + SD) 2.0 + 0.6, 12.5 + 2.1 
and 1.1 + 0.4 g/1, respectively); the Waaler-Rose, latex 
fixation test and ANA were negative. The complement factors 
were within the normal range; no circulating immune complexes 
were demonstrable by the Clq binding assay. Treatment with 
aurothioglucose was started: after a test dose of 10 mg, 
weekly injections of 50 mg were given. After a cumulative 
dose of 460 mg aurothioglucose, the patient developed gene­
ralized dermatitis and stomatitis. In spite of dose reduction 
these symptoms exacerbated and soon made it necessary to stop 
gold injections. At that time the laboratory findings were as 
follows: ESR 10 mm after one hour, haemoglobin 7.4 mmol/l. 
Platelets 329 χ 10 9/1 and leucocytes 6.5 χ 10 9/1 with a normal 
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Figure 2. Immunoglobulin levels in r e l a t i o n to aurothioglucose treatment 
d i f fe ren t i a l count without eos inophi l i a . Hepatic and renal 
function t e s t s were normal and the Waaler-Rose t e s t and la tex 
f ixat ion t e s t were negative. However, ANA had become pos i t ive , 
as had the Clq binding assay 1,7%). Serum immunoglobulins as 
detected by radial immunodiffusion revealed undetectable IgA 
levels ( less than 0.02 g/1 ) IgM below normal (0.11 g/1) and a 
normal IgG (11.47 g/1) (see also figure 1) . Gold therapy was 
stopped and serum immunoglobulins, ANA and Clq binding were 
regularly determined. The serum IgA level continued to be un-
detectable during a 9-month follow-up period, whereas IgM and 
1 0 0
Ί 
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IgG serum levels gradually increased (figure 1 ) . The Clq bin-
ding assay became negative again, but the ANA remained posi-
tive. During the follow-up period the patient developed no 
signs or symptoms associated with IgA deficiency, i.e. gastro-
intestinal or pulmonary abnormalities. 
Additional immunological studies revealed that the patient 
had no detectable antibodies against IgA in the serum and no 
secretory IgA in the saliva. Lymphocyte stimulation tests 
using Concanavalin A, PHA and PWM as well as specific stimuli 
including PPD, candida, trichophyton, mumps and varidase gave 
normal values. Immunofluorescence studies of a biopsy specimen 
from the small intestine revealed normal numbers of IgA, IgM 
and IgG-positive plasma cells. 
DISCUSSION 
The patient described developed selective IgA deficiency du-
ring treatment with aurothioglucose. To our best knowledge 
this is the first description of IgA deficiency during treat-
ment with this drug. The other patient developing gold-asso-
ciated IgA deficiency was treated with aurothiomalate ( 5 ) . 
Theoretically, IgA deficiency can result from either decreased 
IgA synthesis or an increased loss or catabolism of IgA. 
Although we cannot rule out the latter possibility completely, 
it seems unlikely that this was involved in our patient. To 
begin with, antibodies against IgA could not be detected. In 
addition, if increased loss of IgA were the cause of the de-
ficiency it would likely have been accompanied by persistent 
low levels of the other immunoglobulins, which was not the 
case. In fact, a defect in IgA synthesis or secretion by plas-
ma cells seems much more likely. 
It has been reported that a deficiency of serum IgA is often 
accompanied by a deficiency of secretory IgA ( 6 ) . The absence 
of secretory IgA in the saliva strongly suggests that this was 
also the case in our patient. On the other hand the immuno-
fluorescence data on the small intestine indicate that plasma 
cells in the lamina propria were able to synthesize IgA. This 
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Observation would suggest that the IgA deficiency of our pa­
tient was probably due to a defect in IgA secretion rather 
than in manufacturing by the plasma cells. The mechanism of 
this defect is unknown, but published data show a striking 
association between selective IgA deficiency and disorders 
of the T-cell system (7,8). One possibility may therefore be 
that aurothioglucose affects immunoglobulin production at the 
T-cell level, as suggested for D-penici11 amine (9). Our data 
showing normal lymphocyte function test values, are not ne­
cessarily in disagreement with this observation. 
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SUMMARY 
Loose stools, one of the most frequent adverse reactions as-
cribed to the orally absorbed gold compound auranofin, was 
studied during a long-term trial. At some time during the stu-
dy 44% of the patients reported the occurrence of loose stools. 
No infective cause or signs of malabsorption were found; nor 
were loose stools caused by the presence of osmotically active 
substances in the gut lumen. Arguments for a direct effect of 
auranofin on the ion and water absorption in the intestine are 
given. Although no morphological studies on biopsy material 
are available, the proven side effect of the drug does not 
seem to necessitate discontinuation of treatment in patients 
as toxic to gut function. 
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INTRODUCTION 
Gold compounds have been used in the treatment of rheumatoid 
arthritis since 1928 (1,2). Several double blind studies have 
demonstrated their therapeutic value. However, the drugs fre-
quently give rise to adverse reactions (3,4,5). Approximately 
80ÍÜ of such reactions comprise rashes, pruritus, stomatitis 
and mild proteinuria. Although adverse reactions involving the 
gastro-intestinal tract are rare, they are usually serious; 
gold-induced enterocolitis has been reported and in more than 
50 percent of these patients ended fatally (6,7). Since Finkel-
stein et al. (8) reported in 1976 that auranofin, an orally 
absorbed gold compound, was wel 1-tolerated and effective as 
an antirheumatic drug as well, many studies on auranofin have 
been done in different countries. Unlike the intramuscularly 
administered gold salts, auranofin seldom caused rash, pruri-
tus, stomatitis and proteinuria, but gastrointestinal symp-
toms, mostly loose stools, were frequently observed. In this 
report we present data on this adverse reaction during a long-
term trial with auranofin. 
PATIENTS AND METHODS 
Patienta. In October 1980, a one-centre patient blind study 
comparing auranofin and aurothioglucose was started. All 
patients had definite or classical rheumatoid arthritis ac-
cording to the criteria of the American Rheumatism Association 
(9). The clinical and laboratory characteristics of the pa-
tients on auranofin are given in table I. All patients were 
treated with non-steroidal anti-inflammatory drugs (NSAID) 
simultaneously with the gold therapy; no other medication was 
allowed. Patients on aurothioglucose started with a test dose 
of 10 mg, followed by 50 mg weekly up to a cumulative dose of 
1000 mg. The dose was then reduced to 50 mg every 2-4 weeks. 
Patients on auranofin received 6 mg as a single morning dose 
daily throughout the study. Patients were randomly allocated 
to either auranofin or aurothioglucose. None of the patients 
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Table I. Clinical and laboratory characteristics of the patients with and 
without loose stools. Mean + SD and (in parentheses) range are given. 
loose stools normal stools 
Number and sex of patients 11j 10F - IM ΙΊ; 7F - 7M 
Age (yrs) Iti + \k (25-68) 53 + 10 (38-66) 
Seroposi ti ve 10 11 
ESR (mm after 1 h) 61 +U\ (23-112) 62 + 3 8 (lif-T»?) 
Hb (mmol/l) 7.1+0.8(5.8-8.0) 7.7+1.2(5.6-9.3) 
Serum gold (yg/100 ml) 63 + 31 (i»0-97) 57 + 29 (35-125) 
had had gastro-intestinal disease or symptoms before the study. 
To minimize the influence on the bowel habits, the patients 
were asked to make no deliberate change in their diet during 
the study. 
Examinations of patients with loose stools. If a patient re­
ported loose stools lasting more than one week, the following 
examinations were performed: plasma electrolytes, serum cho­
lesterol, stool examination for pathogenic flora, ova and 
parasites, occult blood and Sudan III staining to note the 
presence of excess fat. In accordance with the protocol of 
the trial the following examinations were also performed: 
hemoglobin, platelets, white blood cell count and differential 
smear, serum iron, total proteins and blood sugar. Serum gold 
levels were assessed by atomic absorption spectroscopy using 
a Perkin-Elmer model 5000 with a graphite furnace (Perkin-
Elmer, HGA 4 0 0 ) . Samples for serum gold level determination 
were taken between 13.00 hrs and 16.00 hrs at visits to the 
outpatient clinic. 
Earlier experiments at our department had revealed a flat 
serum level versus time curve throughout the day for the oral 
gold when a plateau level of gold had been reached approxima­
tely at week 8 of treatment. 
In three patients with daily loose stools for a period of se-
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vera! weeks or longer, total daily stools were collected for 
two days during treatment and for three days after oral gold 
therapy had been stopped. In these three patients the following 
examinations were also performed during treatment: D-xylose 
test, vitamin B12 absorption test (Schilling test), a glucose 
breath test, the total daily stool weight (wet and d r y ) , so-
dium and potassium content of the feces and osmolality mea-
surements of the stools. Feces for osmolality measurements 
were collected in plastic bags and immediately stored at -20 oC 
until analyzed. For analysis the stool was thawn, homogenized 
and, if necessary, diluted with sterile water. 
Definitions. Loose stools were defined as a relative increase 
in frequency of bowel movements and in fluidity of feces as 
compared with the usual bowel habit of the same individual, 
the daily wet weight of the stools is usually not in excess 
of 400 g. 
Osmotic diarrhea was defined according to Fordtran (10) as 
stools having an osmolality far in excess than twice the sum 
of the concentrations of sodium and potassium in the stool 
water. The osmolality of fecal fluid in normal subjects ob-
tained by high speed centrifugation is, according to Wrong 
(11): 475 + 66 mosmol/kg; it contains 32 + 19 mmol/1 sodium 
and 70 + 33 mmol/1 potassium (mean + S D ) . 
RESULTS 
Clinical findings. Of the 26 patients treated with aurothio-
glucose, only one experienced a period of loose stools for 
more than one week, starting after return from vacation. Of 
the 25 patients on auranofin, 11 had loose stools for a longer 
period at some time during treatment (figure 1 ) . The frequency 
of loose stools varied from one to eight times a day. However, 
the occurrence of symptoms during treatment was not a constant 
phenomenon in all patients; three of the eleven patients had 
loose stools on only 3-4 days a week and normally formed feces 
on the other days. All patients reported abdominal cramps, 
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Figure 1. Data on the onset, duration and intensity of loose stools in 
the auranofin treated patients. 
occurring mostly in the first hours after the ingestion of 
the tablets, and they were free from these symptoms after pas-
sing the stools. None of the patients experienced loose stools 
in the evening and during the night.One patient (no.22) with 
loose stools, often of watery consistency, and episodes of 
abdominal cramps six to eight times a day, dropped out. This 
resulted in prompt discontinuation of the production of the 
loose stools, and the patient regained her original bowel 
habits, i.e. once per three days. Rechallenge in this case 
was not performed. In four other patients (nos. 2,19,26,31) 
who dropped out for other reasons, loose stools likewise 
ceased within a few days after withdrawal of the drug. 
Influenae of ferro médication on loose stools. In two patients 
the loose stools stopped immediately after introduction of a 
concomitant ferro preparation for iron deficient anemia. Al-
though this medication was discontinued later on, these two 
patients regained their normal bowel habit of the period be-
fore the gold treatment was started. The auranofin treatment 
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was not changed in the whole period. 
Laboratory data. In all patients the plasma electrolytes, to­
tal protein, blood sugar and serum cholesterol showed no ab­
normalities. There was no pathological flora in the stool cul­
tures. Examination for occult blood and Sudan III staining for 
evidence of steatorrhea were also negative. In the three pa­
tients studied more extensively, the D-xylose test, the Schil­
ling test and the glucose breath test were normal. The total 
daily stool weight (wet) and the osmolality measurements were 
also within normal limits. However, aberrant values for stool 
electrolytes and dry weight of feces were found. As shown in 
figure 2, patients with loose stools had higher stool sodium 
concentrations than those without loose stools. In contrast, 
potassium concentrations were lower in patients with loose 
stools than in those without loose stools. The stool electro­
lytes and dry weights of the three patients studied extensive-
Na* ( m mol/l) 
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Figure 2. Values of stool electrolytes in auranofin treated patients with 
and without loose stools (I and II respectively) and patients treated 
with intramuscular gold and normal controls (III and IV respectively). 
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Table I I . Stool e l e c t r o l y t e s and stool dry weights in the three p a t i e n t s 
s tud ied dur ing and a f t e r the auranof in med ica t i on . 
p a t i e n t du r ing t reatment a f t e r w i thdrawal of t reatment 
no. 
Na+ K+ dry we igh t * Na+ K+ dry weight 
(mmol/1) (mmol/ l ) X (mmol/1) (mmol/1) % 
1 8it 43 8 10 57 30 
2 41 58 18 8 78 26 
3 50 47 17 6 75 23 
* Dry weight is expressed as the percentage o f the wet weight of the s too l s 
a f t e r f reeze d r y i n g . 
l y a re g i ven i n t a b l e I I . A f t e r d i s c o n t i n u a t i o n of t r e a t m e n t , 
the va lues were n o r m a l i z e d . Dur ing the s t u d y , changes i n body 
we igh t or change i n serum go ld l e v e l i n r e l a t i o n to the occu r -
rence o f loose s t o o l s were not obse rved . 
D I S C U S S I O N 
A u r a n o f i n , a new o r a l l y absorbab le go ld compound, i s under i n -
v e s t i g a t i o n i n many c o u n t r i e s f o r i t s e f f i c a c y and s a f e t y i n 
the t r e a t m e n t o f rheumato id a r t h r i t i s . We s t u d i e d the most 
f r e q u e n t adverse r e a c t i o n t o t h i s d r u g , the occur rence o f 
l oose s t o o l s , i n o r d e r t o de termine i t s c l i n i c a l c h a r a c t e r i s -
t i c s and i t s p o s s i b l e u n d e r l y i n g mode of a c t i o n . 
Rheumatoid p a t i e n t s are o f t e n less mob i le t han h e a l t h y p e o p l e ; 
t h i s l ack o f a c t i v i t y may a t l e a s t p a r t l y be r e s p o n s i b l e f o r t h e i r 
r e p o r t e d tendency to c o n s t i p a t i o n . In t h i s r espec t l oose s t o o l s 
are a welcome e x t r a - e f f e c t o f the d r u g ; on the o ther hand , i n 
terms o f t o x i c o l o g y , the phenomenon cou ld be a s ign o f s e r i o u s 
and unaccep tab le damage, n e c e s s i t a t i n g d i s c o n t i n u a t i o n o f the 
d r u g , a t l e a s t i n the i n d i v i d u a l , or even removal o f the drug 
f rom the marke t . R e c e n t l y , severa l a l g o r i t h m s have been pu-
b l i s h e d ( 1 2 , 1 3 , 1 4 ) f o r assessment o f the p r o b a b i l i t y o f ad -
verse d rug r e a c t i o n s . In o rder to e s t a b l i s h whether t h e r e i s 
a causal relationship between loose stools and auranofin admi­
nistration, we applied the simple method for estimating the 
probability of adverse reactions described by Naranjo et al. 
(12). According to their method, loose stools was classified 
as a definite adverse reaction to auranofin. 
In this report we demonstrate that 44% of the patients on 
auranofin experienced abdominal cramps and loose stools at 
some time during the treatment. This side-effect did not oc­
cur at a specific time after starting the drug. Some patients 
experienced it immediately after medication was started; in 
other patients it appeared only after they had taken the drug 
for several months. 
Loose stools is sometimes a transient phenomenon: some patients 
regained their normal bowel habit after some time, although 
no change in medication had taken place. An infective cause 
or signs of malabsorption have not been found in these patients, 
Since the serum gold levels were not different in the aurano-
fin-treated patients with or without loose stools, gold ab­
sorption was not affected. We also demonstrated in this study 
that the loose stools were not the consequence of the presence 
of unusual amounts of non absorbable, osmotically active sub­
stances in the gut lumen: the osmolality of the feces was nor­
mal. The clues to a direct effect of auranofin on the gut mu­
cosa to be considered were: 
a. the lack of correlation between the serum gold level and 
the occurrence of loose stools. 
b. time relationship: most of the patients complained of ab­
dominal cramps and loose stools in the first 3-4 hours after 
ingestion of the tablets. 
с effect of stopping auranofin: immediately after stopping 
the medication, the loose stools nearly always disappeared. 
d. effect of dose reduction: disappearance of the loose stools 
has been observed after reducing the dose of auranofin medi­
cation or dividing the dose over the day (15). 
The data on the stool electrolytes in patients with loose 
stools indicate a net accumulation of fluid and electrolytes 
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in the intestine. These changes may be brought about either by 
inhibition of ion and water absorption or by stimulation of 
fluid secretion, or by a combination of both. Mechanisms in-
volved could be: an increase in mucosal permeability, altera-
tion in active ion transport processes or increase in mucosal 
cyclic AMP. A comparable effect has been seen with several 
laxatives like ricinoleic acid (16,18), dioctyl sodium sulfo-
succinate (19,20) and bisacodyl (21,22). The action of these 
drugs, however, also results in increased potassium secretion 
(which has not been found with auranofin). A direct effect on 
intestinal motor activity is another possibility in the patho-
genesis of loose stools in these patients; however, a causal 
relation between increased motility and diarrhea has never 
been established (23). Recently, a laxative-like effect of 
NSAID was reported (24), causing accumulation of fluid by mu-
cosal membrane damage. All our patients, whether they used au-
rothioglucose or auranofin and whether they had loose stools or 
not, used NSAID concomitantly. Therefore these drugs cannot 
explain the occurrence of loose stools in these patients. 
Additional information, especially a direct study of the in-
fluence of auranofin on the intestinal absorption of water 
and electrolytes, is therefore required in order to determine 
the pathogenesis of the fluid and electrolyte accumulation in 
the gut lumen as the side effect of the drug. We felt it was 
not justifiable to submit the patients with loose stools to 
endoscopic examination with biopsy of the gut mucosa, since 
the non invasive examinations revealed nothing suggestive of 
malabsorption or a major defect of mucosal permeability. Still 
we believe we have demonstrated that loose stools is a proven 
side-effect of auranofin and that, in view of the present data, 
this does not seem to necessitate discontinuation of treat-
ment in the individual patient or removal of the drug from 
the market as toxic to gut function. 
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CHAPTER 7 
MONITORING SERUM GOLD LEVELS DURING TREATMENT WITH AURANOFIN 
AND AUROTHIOGLUCOSE 
PLCM VAN RIEL, FWJ GRIBNAU, LBA VAN DE PUTTE 
SUMMARY 
Serum gold levels were measured in the context of a clinical 
trial, both in patients treated with the parenterally adminis-
tered gold compound aurothioglucose and in patients treated 
with a new orally absorbable gold compound auranofin. No cor-
relation was found between the serum gold level and the degree 
of response nor toxicity on aurothioglucose and auranofin. A 
statistically significant decline in the serum gold level 
after one year (p <0.05) was found in patients treated with 
auranofin, probably not due to insufficient patient compliance; 
it is suggested that a shift from protein-bound gold to cell-
bound gold is the explanation of this. 
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INTRODUCTION 
Since the introduction of gold compounds in the treatment of 
rheumatoid arthritis, several attempts have been made to find 
pharmacokinetic parameters to improve drug efficacy, while 
minimizing undesirable side effects (1-8). Reports on the 
question whether serum gold levels correlate with clinical re-
sponse have so far been contradictory. Scoring individual 
responses to gold treatment in the context of a clinical trial, 
we decided to make another attempt to correlate serum gold 
levels with the degree of response to aurothioglucose as well 
as to auranofin, a new orally absorbable gold compound (9). 
The clinical trial compared the efficacy and toxicity of the 
two drugs. From the literature we know that toxic and non-
toxic patients treated with parenterally administered gold 
compounds do not differ in serum gold levels (4). However, 
with respect to the most frequent adverse reaction to auranofin 
treatment, i.e. loose stools, no evidence is yet available 
as to whether serum gold levels in patients with loose stools 
differ from those in patients without loose stools. 
METHODS 
Patienta. Fifty-two patients with active classical or definite 
rheumatoid arthritis according to the revised ARA criteria 
(10) were selected for a single blind 52-week study comparing 
the efficacy and safety of auranofin and aurothioglucose. No 
concomitant medication for rheumatoid arthritis was allowed, 
except non-steroidal anti-inflammatory drugs. Clinical charac-
teristics of these patients, admission criteria, types, course 
and frequency of gold toxicity during the first year of treat-
ment are described elsewhere (9). 
Gold médication. Patients on aurothioglucose (20% oily suspen-
sion, Noury-Pharma, Oss, The Netherlands) received 50 mg auro-
thioglucose per week by intramuscular injection up to a cumu-
lative dose of 1000 mg; thereafter the injections were given 
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every two weeks up to a cumulative dose of 1500 mg, after which 
50 mg was given every three weeks until the end of the study. 
Patients on auranofin (SK&F, The Hague, The Netherlands) re-
ceived 6 mg daily as a single morning dose throughout the 
study. 
Criteria of response. Patients were divided into excellent, 
moderate and non-responders, using a newly developed method 
(11) which included the degree of improvement as well as 
the degree of disease activity attained; this method was 
adapted from the activity index described by Mallya et al. 
(12). 
Adverse reaotions. Patients were considered to have developed ad-
verse reactions probably due to the gold compound, if no alterna-
tive cause for the observed reaction was found and if clearance 
or diminution of the adverse reaction was seen after cessation of 
treatment. Fourteen patients treated with aurothioglucose had se-
vere adverse reactions in the course of a 12-month follow-up, ne-
cessitating suspension or discontinuation of treatment. Thirteen 
of these patients had generalized dermatitis (one had stomatitis, 
another had proteinuria at the same time) and one patient had a 
polyneuropathy. Only two auranofin-treated patients had severe ad-
verse reactions necessitating discontinuation of treatment (derma-
titis, diarrhoea). Eleven patients reported the occurrence of 
loose stools during auranofin treatment. 
Collection of blood samples and gold analysis . Blood samples 
were collected at 2-month intervals prior to the next in-
jection. Whole blood was collected in stoppered plain vacu-
tainer tubes. Serum was obtained by centrifuging at 1000 g 
for 20 minutes and was stored frozen until analysed. Serum 
gold levels were assessed by atomic absorption spectroscopy 
(Perkin-Elmer, model 5000) with a graphite furnace (Perkin-
Elmer, HGA 400) (13). The reproducibility of gold determina-
tion in serum at a concentration of 50 ug/100 ml was expressed 
as coefficient of variation, and turned out to be less than 3%. 
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Figure 1. Course of the serum gold level in eleven auranofin-treated 
patients 
RESULTS 
Course of the eevum gold levels. The serum gold level in the 
aurothioglucose-treated patients reached a plateau level and 
then declined in proportion to the reduction of the adminis­
tered gold dose. In the auranofin-treated patients a plateau 
serum gold level was reached after 16 weeks of treatment. Des­
pite constant dosing, a gradual decline in serum gold level 
was observed thereafter in the patients treated for at least 
one year; it was statistically significant at week 52 (p <0.05, 
paired t-test; figure 1 ) . The patients withdrawn during the 
first year of treatment showed a similar decline in serum gold 
level. Their serum gold levels (mean + SD) at week 16 and 24 
were 59 + 25 yg/100 ml and 51 + 16 мд/100 ml, respectively 
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о Table I. Serum gold levels (μς/ΙΟΟ ml, mean + SD) arranged according to degree of response in auranofin-
and aurothioglucose-treated patients; η = number of patients. 
Therapy AURANOFIN AUROTHIOGLUCOSE 
weeks of excellent moderate no 
therapy response response response 
M SD η M SD η M SD η 
excellent moderate по 
response response response 
M SD η M SD η Μ SD η 
θ 
62 + 23 5 67 + 3*» 6 52 + 22 12 319 + 109 9 259 + 100 7 229 + 75 5 
16 72 + 41 5 79 + 26 6 56 + 21 11 333 + 6 8 9 259 + 57 7 270 + 95 5 
2k 72 + ι»8 5 51 + 19 6 Ί6 + 14 11 240 + 103 7 198 + 62 7 201 + 78 4 
40 55 + 24 5 36 + 13 3 44 + 8 5 191 + 8 2 5 162 + 57 5 
52 54 + 17 5 34 + 11 3 39 + 4 3 117 + 17 5 158 + 93 5 
ТаЬЪе II. Serum gold levels (μς/ΙΟΟ ml, mean + SD) in patients with and without toxic reactions to auranofin 
and aurothioglucose; η = number of patients. 
Weeks of therapy AURANOFIN AUROTHIOGLUCOSE 
loose stools 
M SD η 
no loose stools 
M SD η 
toxic group 
M SD η 
non-toxic group 
M SD η 
63 + 31 11 57 + 29 12 279 + 3 8 11 2Ή + 104 11 
16 
24 
40 
52 
7 0 + 2 3 10 
5 4 + 1 4 10 
4 9 + 1 2 4 
4 6 + 1 4 4 
5 8 + 3 1 12 
50 + 29 12 
46 + 19 
44 + 17 
293 + 6 9 10 
224 + 3 7 7 
2 1 1 + 3 6 3 
136 + 71 3 
264 + 8 3 11 
215 + 95 11 
166 + 7 1 8 
169 + 8 3 8 
(0.05 < ρ <0.1, paired t-test). 
Therapeutic response : correlation with serum gold levels. No 
significant differences in serum gold levels were found between 
excellent, moderate or non-responders to aurothioglucose and 
auranofin treatment (table I ) . 
Adverse reactions : correlation with serum gold levels. No dif­
ferences were found in the serum gold levels of aurothioglu-
cose-treated patients with and without adverse reactions. The 
auranofi η-treated patients with and without loose stools 
(table II) showed no significantly different serum gold levels. 
DISCUSSION 
Although it has been possible to measure serum gold levels by 
atomic absorption spectroscopy for more than 14 years, reports 
on whether or not serum gold levels correlate with clinical 
response to parenterally administered gold compounds are still 
contradictory (1-8) Some investigators advocate an individua­
lized gold therapy regimen with maintenance of serum gold 
levels between 300-400 yg/100 ml during aurothiomalate treat­
ment in order to obtain a favourable response ( 6 ) . In this 
study we found no correlation between the individual serum 
gold levels and response to aurothioglucose treatment. Due 
to the gradual decline of the qold dose in the aurothioglucose-
treated patients, the excellent responders as well as the mo­
derate responders in our study had far lower serum gold levels 
than those advocated by Lorber (6). In the auranofin-treated 
patients we did not find a correlation between serum gold 
level and therapeutic response either. 
In agreement with the literature we found no differences in 
serum gold levels between toxic and non-toxix aurothioglucose-
treated patients. As already suggested by us elsewhere on the 
basis of preliminary data, no differences were found in the 
course of the serum gold levels between patients with and 
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without loose stools on auranofin treatment ( 1 4 ) . No other 
reports on the absence of this relationship exists. 
Surprisingly, we found that most auranofin-treated patients 
showed a spontaneous decline of the serum gold level after the 
plateau had been reached. It was evident from the return ta-
blet count that this decline was not related to insufficient 
patient compliance. Sixty-three percent (5 out of 8) of the 
patients with an excellent or moderate response after 10 
months of treatment showed a decline in serum gold level, 
while only 20% (1 out of 5) of the non-responders did so at 
that time (p = 0.1, Fisher exact t e s t ) . Since other investi-
gators found stable whole blood gold concentrations during 
long-term treatment with auranofin, this decline in serum gold 
level may be due to a shift from protein-bound gold to cell-
bound gold; in fact we did not measure the amount of gold 
bound to cellular blood constituents in a systematic longitu-
dinal way. 
In summary we have shown the following: 
1. No correlation exists between serum 
peutic response to either auranofin or 
ment. Our excellent responders to aurot 
had far lower serum gold levels than th 
2. Patients with loose stools on aurano 
differ in serum gold levels from patien 
3. Most patients showed a decline in se 
long-term treatment with auranofin; thi 
nificant after one year. We conclude th 
the need to measure whole blood gold co 
as serum gold concentrations in future 
decline in serum gold level may be due 
distribution of the gold compound. 
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SUMMARY 
Three different methods of determining the cell-bound gold 
concentration were compared in patients given intramuscular 
and oral chrysotherapy for rheumatoid arthritis. We found a 
strong correlation between the different methods, and no dif 
ference between two washing procedures. 
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INTRODUCTION 
Gold salts have been used in the treatment of rheumatoid ar-
thritis since 1928 (1-2). Many efforts have been made to study 
the correlation between gold pharmacokinetics and clinical ef-
fect and toxicity, in order to improve drug efficacy and mini-
mize undesirable side-effects. 
Pharmacokinetic parameters which have been demonstrated to 
have no or contradictory correlations with pharmacodynamics 
include plasma and serum gold levels (3- 6 ) , binding of gold 
to non-albumin serum proteins ( 7 ) , total body gold retention 
and urinary gold excretion (8,9). Recently, a correlation has 
been suggested between the gold concentration in erythrocytes 
and the incidence of toxic reactions (10), although other 
authors reported absence of this correlation (7). These con-
tradictory results may at least partly be due to different 
procedures of washing erythrocytes and different methods to 
determine the cell-bound gold (CBG) concentration. 
Auranofin, an orally absorbable gold compound, has been found 
to be associated with erythrocytes in a greater extent than 
the intramuscularly administered gold salts (11). We decided 
to compare the different methods of determining CBG described 
in the literature in the context of a single blind study on 
auranofin versus aurothioglucose in patients with rheumatoid 
arthritis. This report presents the findings of two different 
washing procedures and three different ways of determining 
the CBG concentration, and describes the influence of storage 
of blood samples at room temperature. 
MATERIALS AND METHODS 
Patients and schedule of gold administration. The patients (8 
on aurothioglucose and 11 on auranofin) had a definite or 
classical rheumatoid arthritis fulfilling the criteria of the 
American Rheumatism Association (12). The usual parameters 
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Table I, Characteristics of the patients treated with auranofin and auro-
thioglucose, respectively; mean + SD and (in parentheses) range are givení 
auranofin aurothioglucose 
Number and sex 11; 6F-5M 8; 5F-3M 
of patients 
Age (yr) 5^+11 (38-6?) 64+10 (41-69) 
Seropos i t i ve 7 5 
ESR (mm a f t e r 1 h) 26.7+19-2 (12-62) 27.4+20.4 (9-66) 
Hb (g/100 ml) 12.6+1.0 (11.4-14.0) 12.7+1.3 (11.1-14.7) 
E ry th rocy te count 4.31+0.38 (3 .71-4 .80) 4.27+0.26 (3 .71-4 .87) 
(1012/1) 
Plasma go ld 47.6+24.3 (31-98) 112.6+49.2 (40-178) 
(ug/100 ml) 
CBG (pg/100 ml) 20.5+3-7 (15-25) 6.0+7.7 (0-19) 
« Figures on ce l l - bound gold (CBG), obta ined by the d i r e c t method. 
f o r assess ing t h e r a p e u t i c response i n rheumato id a r t h r i t i s were 
measured. Only m e d i c a t i o n w i t h n o n - s t e r o i d a l a n t i - i n f l a m m a t o r y 
drugs was a l l o w e d s i m u l t a n e o u s l y w i t h go ld t h e r a p y . C l i n i c a l 
and l a b o r a t o r y c h a r a c t e r i s t i c s of these p a t i e n t s are g i ven i n 
t a b l e I . In some p a t i e n t s , not a l l d e t e r m i n a t i o n s to be d e s c r i b -
ed cou ld be made. A u r a n o f i n was p r o v i d e d by SK&F, The Hague, , 
The N e t h e r l a n d s ; the i n t r a m u s c u l a r l y g i ven go ld s a l t was au ro -
t h i o g l u c o s e (20% o i l y suspens ion , Noury Pharma, Oss, The Ne ther -
l a n d s ) . P a t i e n t s on a u r o t h i o g l u c o s e s t a r t e d w i t h a t e s t dose 
o f 10 mg, a f t e r which 50 mg weekly was g iven up to a c u m u l a t i v e 
dose o f 1000 mg, t h e r e a f t e r the dose was reduced to 50 mg 
every 2-4 weeks. P a t i e n t s on a u r a n o f i n r e c e i v e d 6 mg d a i l y as 
a s i n g l e morning dose w i t h b r e a k f a s t t h r o u g h o u t the s t u d y . 
Blood samples were taken f rom p a t i e n t s r e c e i v i n g the drugs f o r 
a t l e a s t s i x months. A l l p a t i e n t s t r e a t e d w i t h a u r o t h i o g l u c o s e 
i n c l u d e d i n t h i s s t u d y , got t h e i r i n j e c t i o n s a t f o r t n i g h t l y 
or l o n g e r i n t e r v a l s . 
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Collection and preparation of samples for gold assay. Blood 
samples from patients on aurothioglucose were collected prior 
to the next injection. Venipunctures were made between 1.00 
and 4.00 p.m.; patients on aurothioglucose were given their 
injection of the drug just after venipuncture. Blood was col 
lected in stoppered calibrated heparinized tubes and the hae-
matocrit value was measured and an erythrocyte count was made. 
For washing procedure I the erythrocytes were separated from 
the plasma by centrifuging at 1000 g for 20 minutes. The iso-
lated erythrocytes were washed 5 times with sterile isotonic 
saline; after this the cells were suspended in saline up to 
original blood volume (giving sample I) and an erythrocyte 
count was made. For washing procedure II a centri fugation pel-
let of erythrocytes was washed twice with Hymans' washing me-
dium (13) and suspended with saline up to the original blood 
volume (giving sample II). An erythrocyte count was also made. 
Finally, some blood was immediately stored at -20 oC until 
measurement. The samples I, II and III were likewise stored 
frozen until measurement. Some blood was kept at room tempe-
rature and processed the next day, using the washing procedure 
with saline (giving sample III); storage of a sample outside 
the refrigerator is probably not uncommon in a hospital situa-
tion. The amount of erythrocyte loss caused by the washing 
procedures proved to be less than 5%. The coefficient of va-
riation of the haematocrit determination and erythrocyte 
counts was 2%. 
Method of gold determination. Gold levels in plasma, erythro-
cytes, whole blood and washing fluid were assessed by atomic 
absorption spectroscopy (Perkin-Elmer, model 5000), with a 
graphite furnace (Perkin-Elmer, HGA 400 ) ; Sheathing gas, puri-
fied nitrogen (flow rate = 450 ml/min). Instrument settings: 
spectrophotometer 242.8 nm, integration time 5 sec, slit width 
0.7 nm, hollow cathode lamp (10 m A ) . Background: deuterium 
lamp. Thermal treatment: drying at 120 oC, hold time 20 sec; 
ashing at 900 oC, hold time 30 sec; atomization at 2400 oC, hold 
time 10 sec. Stop flow during atomization. Measurements were 
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Table I I . Reproducibility of gold determinations at various concentrations 
(30, 50 and ISO yg/100 ml) of gold chloride added to plasma or whole blood, 
expressed as coefficient of variation of 10 measurements. 
pg/lOO ml coefficient of variation (percent) 
plasma whole blood 
30 h.3 6.8 
50 2.8 З.'» 
150 2.4 l.k 
made by comparison of the absorbance peaks. The standard solu­
tions were prepared from a stock solution (gold chloride 1 mg/ 
ml, BHD, Buschwig, Amsterdam, The Netherlands). This solution 
was diluted either with a 20% albumin solution or whole blood 
depending on the sample, in concentrations of 5-10-15-20-30-
50-75-100-150 yg/100 ml. 10 μΐ of a sample was injected. 
Methods of d e t e r m i n i n g CBG. A. CBG expressed in absolute terms 
(concentration in cell suspension made by suspending the ery­
throcytes washed with saline up to the original blood volume 
(direct method).B. CBG expressed as amount of gold in 1 0 x 1 0 ^ 
erythrocytes per litre, washed with saline; this was done to 
compare our results with data from the literature (direct me­
thod). С CBG calculated by subtracting the plasma gold concen­
tration corrected fro haematocrit from the whole-blood gold 
concentration (indirect method). 
The coefficient of variation of 10 determinations at the re­
spective gold concentrations in whole blood and plasma are 
shown in table II. The error in CBG measurements made by method 
С due to multiplying and subtracting different figures with 
their respective coefficient of variation, was comparable 
with the error made by the different washing procedures; both 
were in the order of 6%. 
Ethieal a s p e c t s . Patients had given informed consent for the 
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CBG(Mg/100ml) 
4 0 т 
30-
20-
10-
0-
CBG(Mg/100ml) 
Figure 1. CBG determined after the 
two different washing procedures 
(sample I .'saline; sample ll:Hymans' 
solution) in both treatment groups. 
Figure 2. CBG determined after in­
stantaneous processing (I) and af­
ter storage of the blood sample for 
one day at room temperature (111) 
for both treatment groups. 
CBG 
ц д / Ю О т І М ^д/100гг|/10 10"/l (о) мд/100тІ(Д> 
aurothioglucose г 5 0 
n = 7 
4 0 
3 0 
1 0 
о 
Figure 3. Comparison between CBG determined by three different methods. 
A. Direct method, CBG expressed in pg/100 ml. 
B. Direct method, CBG expressed in pg/100 ml in 10x1012/l erythrocytes. 
С Indirect method, CBG expressed in цд/100 ml. 
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drug trial; the Hospital Ethics Committee had given approval 
to the protocol. 
RESULTS 
The CBG values determined with the two washing procedures and 
expressed in absolute terms (samples I and II) are equal; this 
applies to both treatment groups. Figure 1 illustrates the 
findings in the individual patients. In the auranofin-treated 
patients the mean + SD for sample I is 20.5 + 3.7 yg/100 ml; 
and for sample II it is 20.5 + 2.9 yg/100 ml, respectively. In 
the aurothioglucose-treated patients it is 6.0 + 7.7 yg/lOO ml 
for sample I, and 5.0 + 8.0 yg/lOO ml for sample II. 
Storage of a whole blood sample at room temperature for one 
day does not influence the CBG in the aurothioglucose-treated 
patients; mean + SD for sample I: 6.0 + 7.7 yg/100 ml for 
sample III: 5.5 + 7.8 yg/100 ml (figure 2 ) . 
In the auranofin treated patients there is a slight but statis­
tically significant increase in CBG (p <0.05, paired t-test); 
mean + SD for sample I: 22.2 + 3.8 цд/100 ml; sample III: 23.8 
+ 4.0 ug/100 ml. The three different methods of calculating 
the CBG correlate well (figure 3 ) . Method В with method A: 
r = 0.93; method С with method A: r = 0.96. The amount of 
gold in the washings ranges from 2 to 17% in the auranofin-
treated patients from 0 to 16% in the aurothioglucose-treated 
patients. Comparison of the calculated CBG (method C) with the 
CBG expressed in absolute terms of non-washed erythrocytes 
reveals no difference. The amounts of gold in the erythrocytes 
(samples I, II and I I I ) , whole blood and plasma as well as 
data about the smoking habits of the individual patients are 
given in table III. The CBG values of smokers in the auranofin 
group were not higher than in the non-smokers of that group. 
The two patients in the aurothioglucose group with the highest 
CBG levels smoked cigarettes, in another patient, who smoked 
cigarettes, no detectable CBG was found. 
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Table III. Gold concentrations, erythrocytes, haematocrits, and smoking habits of 11 patients treated with 
auranofin, and 8 patients treated with aurothioglucose. 
patient no. erythrocytes haematocrit samples whole blood plasma smoker 
10x1012/l \_/\ I II III yg/100 ml ug/100 ml 
auranofin 
1 
2 
3 
it 
5 
6 
7 
8 
9 
10 
11 
3.84 
4.3h 
A.96 
4.08 
4.12 
4.45 
4.43 
4.61 
4.80 
5.02 
4.42 
0.38 
0.39 
0.38 
0.40 
0.39 
0.38 
0.41 
0.41 
0.40 
0.41 
0.38 
18 
25 
24 
15 
21 
20 
23 
25 
17 
20 
40 
18 
22 
23 
17 
20 
20 
-
-
-
-
-
-
27 
25 
17 
21 
-
27 
26 
-
-
-
41 
59 
54 
39 
-
-
59 
58 
41 
43 
107 
aurothioglucose 
31 
54 
40 
34 
43 
58 
44 
40 
31 
31 
98 
-
+ 
-
-
-
-
-
-
+ 
+ 
-
1 
2 
3 
4 
5 
6 
7 
8 
4.48 
4.57 
4.43 
3.88 
4.24 
4.63 
4.12 
4.66 
0.45 
0.40 
0.40 
0.36 
0.40 
0.39 
0.43 
0.42 
17 
0 
0 
19 
4 
2 
6 
0 
20 
0 
0 
15 
0 
0 
5 
0 
20 
0 
0 
15 
0 
2 
6 
0 
69 
81 
51 
192 
39 
63 
-
Ill 
75 
138 
75 
244 
51 
104 
106 
177 
DISCUSSION 
Various methods of calculation and washing of erythrocytes 
have been used in recent studies attempting to establish a 
correlation between the CBG and clinical effects and side-ef­
fects of chrysotherapy (7,10). The results were contradictory, 
probably due to the different methods used. Our study demon­
strated no difference between two washing procedures. We found 
a strong correlation between the three different procedures of 
calculating the CBG. Unlike Pedersen et al (10), we did not 
find any difference between CBG expressed in absolute terms 
and CBG corrected for the erythrocyte count. This may be due 
to the small variation of the erythrocyte counts and haemato-
crits in our patients. Pedersen et al (10) presented no data 
on haematocrit values and erythrocyte counts in their patients, 
but recommended this correction in order to predict which pa­
tients are likely to develop side-effects. In nearly all pa­
tients we detected gold in the washing solution (up to 17% of 
the whole blood gold concentration), whereas Van der Stadt 
et al (7) reported that gold was not removable from the ery­
throcytes . 
James et al (14) and Graham et al (15) recently pointed out 
that higher CBG values found in smokers compared to non-smokers, 
treated with aurothiornai ate. Although the number of patients 
is small, our findings at least do not exclude that some in­
fluence of the smoking habits on the CBG might exist in the 
aurothioglucose treated patients. 
There was a slight but significant increase in CBG in the au-
ranofi η-treated patients when the blood was stored at room 
temperature for one day. In the individual patients the in­
crease was always smaller than the coefficient of variation 
for that concentration. 
Our conclusion is that the contradictory findings in the lite­
rature concerning the value of CBG cannot be explained by dif­
ferent washing procedures or different methods of calculating 
CBG. One possibility remains that the smoking habits of the 
patients in the different studies, are responsible for the 
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contradictory findings. This study demonstrates that informa­
tion on CBG can be obtained without washing the erythrocytes; 
the indirect method of calculating CBG is sufficient. 
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CHAPTER 9 
DISCUSSION AND CONCLUSIONS 
DISCUSSION AND CONCLUSIONS 
As a consequence of the wide clinical spectrum of rheumatoid 
arthritis (RA) on the one hand, and the absence of a specific 
laboratory test as a quantitative parameter on the other, the 
effect of treatment in rheumatological practice is usually 
judged by general assessment. The decision as to whether or 
not a patient with RA is responding is based on clinical and 
laboratory information. In order to substantiate this decision 
the physician considers at the same time partly subjective 
variables such as morning stiffness, the severity of pain, 
number of painful and swollen joints, fatigue as well as ery­
throcyte sedimentation rate and haemoglobin level. 
СЪгпіеаІ trial: merits of auranofin? For use in the single 
blind clinical trial comparing the efficacy and safety of 
aurothioglucose and auranofin in 52 patients with rheumatoid 
arthritis (chapter 2) we formalized this general assessment, 
using multivariate analysis. The index of disease activity 
(IDA) we used comprises the four following variables: morning 
stiffness, number of tender joints, haemoglobin level and 
erythrocyte sedimentation rate; this IDA was adapted from 
the index described by Mallya et al. By means of the IDA we 
were able to study the response of each patient and of patient 
populations as a whole. Many aurothioglucose-treated patients 
had to be withdrawn due to toxic reactions duri ng the fi rst year of 
treatment, whi 1 e on the contrary many auranofi η-treated patients 
were withdrawn after 6 months of treatment due to lack of 
effect. This prompted us to compare patients in both treat­
ment groups who completed one year of therapy (n = 14) as well 
as patients who dropped out during the first year of therapy 
(n = 2 6 ) . In both comparisons aurothioglucose-treated patients 
turned out to have improved more. The auranofin-treated pa­
tients withdrawn because of lack of efficacy (n = 10) were 
treated after withdrawal with D-penici 11 amine ; the majority 
of these responded acceptably well. All in all, auranofin 
turned out to be less toxic but also less effective than au­
rothiogl ucose . In our opinion the therapeutic value of aura­
nofin lies between that of aurothioglucose and that of hydroxy-
chioroquine therapy. 
Genetic faatore •influencing benefit and risk in gold treatment. 
After the report of Stastny in 1977 that genetic factors play 
a role in the pathogenesis of rheumatoid arthritis, several 
studies have demonstrated associations between HLA-antigens 
and the occurrence of side effects of phase II antirheumatic 
drugs. However, to our knowledge only one congress presenta­
tion is available, which discusses the possible association 
between HLA-antigens and responsiveness to drug treatment. 
In agreement with the literature we found (chapter 3) HLA-DR3 
more frequently in patients developing serious toxicity during 
aurothioglucose treatment than in those who did not (35% versus 
9%). Due to the low frequency of severe adverse reactions in 
the auranofin-treated patients, no association with HLA-anti­
gens was found in this treatment group. We demonstrated a 
statistically significant association between the HLA-DR3-
antigen and favourable clinical response to aurothioglucose 
therapy by measuring the individual degree of response in 
patients, including those who had to be withdrawn after 4 
months of treatment. This association was not found in the 
auranofi η-treated patients, probably because fewer patients 
showed an excellent response to auranofin and because only 
3 auranofin-treated patients happened to be HLA-DR3-positi ve, 
versus б in the aurothioglucose group. More extensive studies 
are required in order to establish whether the proneness to 
develop drug toxicity in the DR3-positive group is associated 
with excellent responsiveness, i.e. whether or not the good 
response and the tendency to develop severe toxicity are con­
nected in the same individuals. In order to gain more infor­
mation on genetic influences it is advisable to consider HLA-
typing in controlled clinical studies; it is too early to re­
commend this method for routine clinical practice. 
Immunoglobulin levels: associated with gold-induced toxicity? 
A patient (chapter 5) who developed selective IgA deficiency 
during aurothioglucose treatment and at the same time had 
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Figure 1. Data 'about t o x i c i t y , degree of response, HLA-DR3 p o s i t i v i t y and 
IgA lowering in 25 aurothioglucose treated pat ients. Each symbol represents 
a pat ient. 
general ized d e r m a t i t i s , made us look f o r d i f f e r e n c e s i n immuno­
g l o b u l i n l e v e l s between t o x i c and non-toxic p a t i e n t s . The 
group of t o x i c pat ients (n = 14) had s i g n i f i c a n t l y lower serum 
IgA and IgG leve ls than the non-toxic group, both at the s t a r t 
and during treatment (except f o r IgG at month 12). The serum 
IgA leve l seemed to be the most important wi th regard to 
t o x i c i t y dur ing aurothioglucose t reatment : when the immuno­
g l o b u l i n l e v e l s were compared at the very moment of t o x i c i t y , 
only the IgA leve l and not the IgG (or IgM) leve l was s i g n i ­
f i c a n t l y lower i n t o x i c pat ients than in those not t o x i c 
at t h a t moment. Speculations about a possible r e l a t i o n between 
the serum IgA level and the occurrence of adverse react ions to 
aurothioglucose are presented (chapter 4 ) . The f i g u r e summa-
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rizes data on the aurothioglucose-treated patients: toxicity, 
degree of response, HLA-DR3 positivity andwhetheror not they 
developed a subnormal IgA level. It has been thought that pa-
tients with an adverse reaction respond better than those 
without an adverse reaction; from the admittedly small popula-
tion of patients we studied, it cannot be concluded that toxic 
patients and non-toxic patients respond differently: no gross 
differences can be read from this graphic representation of 
our material. The present data will have to be extended by 
further studies before definite conclusions can be drawn as 
to their value in predicting toxicity. Our data suggest, 
however, that patients with subnormal serum IgA are at parti-
cular risk and may be future candidates for dose reduction 
once IgA becomes subnormal. 
Loose stools: a definite, epeoifia auranofin side effect. A 
change in bowel habits is the most frequent adverse reaction 
to the orally absorbable gold compound. Many (44%) of the 
auranofin-treated patients reported the occurrence of loose 
stools at some time during the study. Arguments for a direct 
effect of auranofin on ion and water absorption are given in 
chapter 6. We felt justified to continue auranofin treatment 
in patients with loose stools, although no data on biopsy 
material were available. In our opinion postmarketing sur-
veillance of this side effect is necessary. 
Monitoring serum gold levels: sense or nonsense? It has been 
suggested that maintenance of serum gold levels above a cer-
tain level (300 pg/100 ml for aurothiomalate) would produce 
better clinical effects, although others claim the contrary. 
Using our method of individual scoring of responses, we stu-
died a possible correlation between serum gold levels and the 
degree of response to aurothioglucose as well as to auranofin 
(chapter 7 ) . We found no such correlation either in the auro-
thioglucose- or in the auranofin-treated patients; the excel-
lent responders in the aurothioglucose group had serum gold 
levels far below 300 pg/100 ml. No differences in serum gold 
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levels were found between patients with and without loose 
stools during auranofin treatment. In agreement with the lite­
rature we found no differences in serum gold levels between 
toxic and non-toxic aurothioglucose-treated patients. The 
serum gold level in most auranofin-treated patients declined 
in the course of one year of treatment. After one year, a 
statistically significant difference (mean serum gold level 
+ SD at 16 weeks: 67 + 30 pg/lOO ml versus 44 + 16 yg/100 ml 
at 52 weeks; ρ <0.05) was found. Since the literature mentions 
constant whole blood gold levels in the plateau phase of au­
ranofin treatment, we suggest that this is due to a change in 
the gold distribution in the blood; we did not measure whole 
blood gold concentrations in all patients. In our opinion 
serum gold monitoring during aurothioglucose treatment is 
useless in clinical practice. For research purposes we advise 
that gold be measured in serum as well as in whole blood during 
auranofin treatment. 
Cell-bound gold: which method of determination? It has been 
suggested that the amount of erythrocyte-bound gold is cor­
related with the incidence of toxic reactions; other investiga­
tors claim the opposite. Since different procedures of washing 
erythrocytes and different methods to determine the cell-bound 
gold concentration had been used, these data were not compa­
rable. We demonstrated (chapter 8) that the different washing 
methods and the different methods of calculating the amount 
of erythrocyte-bound gold could not explain the abovementioned 
conflicting results. Our findings are compatible with the 
suggestion in the literature that the smoking habits of the 
patients in the different studies could be responsible for the 
contradictory findings. It is not necessary to measure CBG: 
we showed that this can reliably be deduced from measuring 
the gold concentration in serum and whole blood, respectively. 
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HOOFDSTUK IO 
SAMENVATTING 
SAMENVATTING 
Dit laatste, Nederlandstalige hoofdstuk is een beknopte weer-
gave, in eenvoudige termen, van hoofdstuk 9, waarin de weten-
schappelijke samenvatting en enkele slotbeschouwingen staan. 
Bij de behandeling van patiënten met reumatoide arthritis, 
waarbij de medikamenteuze therapie overigens één onderdeel 
is in een geheel van maatregelen, worden vaak goudinjekties 
gebruikt. Dit gebeurt al meer dan 60 jaar ondanks het vaak 
voorkomen van bijwerkingen die soms ernstig kunnen zijn. 
Meerdere studies hebben de werkzaamheid van goud bij reuma-
toide arthritis duidelijk aangetoond. Het werkingsmechanisme 
van goud is echter nog steeds onbekend. 
Wanneer de diagnose reumatoide arthritis vaststaat wordt met 
goudinjekties begonnen als er onvoldoende reaktie is op behan-
deling met lichtere middelen, die worden aangeduid met de naam: 
niet-steroidale analgetische antiflogistica. Deze naam geeft 
aan dat: 
- het gaat om stoffen die niet verwant zijn aan bijnierschors-
hormonen (en dus de gevaren van die stoffen ook niet met zich 
meebrengen) 
- het stoffen zijn, die zowel pijnstillend als ontsteki ngsretn-
mend werken. 
Ze worden nogal eens gegeven in combinatie met antimalari amid-
delen. Indien er sprake is van een ernstige, snel tot toenemen-
de gewrichtsschade leidende reumatoide arthritis, kan de be-
handeling met anti mal ari amiddelen worden overgeslagen en wordt 
direct begonnen met goudinjekties in combinatie met genoemde 
m'et-stproidale analgptische antiflogistica. 
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ernstige bijwerkingen te veroorzaken dan het injecteerbare 
goudpreparaat, echter de werkzaamheid was eveneens geringer. 
In hoofdstuk 3 wordt de invloed beschreven, die erfelijkheids-
factoren kunnen hebben op de uitwerking van de geneesmiddel 
therapie van reumatoide arthritis. Gebleken is, dat zowel het 
krijgen van bijwerkingen, als de mate van gunstig reageren op 
goudinjekties, deels door erfelijke factoren van de patient 
worden bepaald. De uitkomsten van ons onderzoek, dat een vrij 
beperkte omvang had, mogen zeker nog niet veralgemeend worden 
tot een omschreven advies. Indien echter uit verdere studies 
over grotere aantallen patiënten zou blijken dat succes-kans 
en kans op bijwerkingen door één en dezelfde erfelijkheidsfac-
tor bepaald worden, is het misschien verstandig deze patiënten 
voortaan al bij voorbaat met een lagere dosis goud te behande-
len. Het is namelijk komen vast te staan, dat ongewenste ne-
venwerkingen van goud minstens voor een deel dosis-afhankelijk 
zijn: verlaging van de dosis kan de bijwerking doen afnemen 
of verdwijnen, met behoud van een redelijk therapeutisch resul-
taat. 
In hoofdstuk 4 worden argumenten gegeven voor een mogelijke 
belangrijke rol van het gehalte in serum van een groep van 
antistoffen (immunoglobuline A, IgA) voor het krijgen van een 
bijwerking van aurothioglucose. In hoofdstuk 5 wordt een pa-
tiente beschreven, die een selectief IgA tekort ontwikkelde 
tijdens behandeling met aurothioglucose; dit ziektegeval was 
aanleiding voor de bestudering van het beloop van de IgA ge-
haltes in het bloed, waarvan hoofdstuk 4 verslag doet. De uit-
komsten daarvan zijn, naar onze mening, dusdanig van belang, 
dat het IgA gehalte voortaan tijdens alle goudbehandelingen 
in onze kliniek wordt gemeten; patiënten met een laag IgA 
gehalte bij het begin van de goudbehandeling, en degenen bij 
wie het gehalte snel en/of aanzienlijk daalt, lopen naar onze 
mening meer kans op een ernstige huidovergevoeligheid. Gaat 
het ziektebeloop bij die patiënten de gunstige kant op, dan 
wordt de gouddosis verlaagd. 
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Brijige ontlasting is de meest voorkomende bijwerking van 
auranofin. De klinische kenmerken van deze nevenwerking, als 
ook argumenten voor een bepaalde verklaring ervan, worden be-
schreven in hoofdstuk 6. Wij vinden het aan te raden, dat ná 
het op de markt komen van auranofin stelselmatig bij alle of 
zeer veel gebruikers wordt bijgehouden, hoe de functies van 
het ingewandstelsel tijdens en ook lang na behandeling met 
auranofin is. Zo'n registratie en bewerking van de verkregen 
gegevens, wordt wel aangeduid met de naam"post-marketing sur-
veillance" van een nieuw geneesmiddel. 
Er is wel betoogd, dat de goudconcentraties in het serum van 
patiënten van belang zijn om de therapie voor het individuele 
geval op maat bij te sturen; andere auteurs betwijfelen deze 
relatie. Onze uitkomsten van onderzoek weergegeven in hoofd-
stuk 7 lieten géén verband zien tussen de serum goudspiegels 
en het krijgen van een bijwerking vaneen van beide goudpre-
paraten, noch bleek er een correlatie te bestaan met de mate 
van reageren op de ingestelde therapie. De meting van goudcon-
centraties in het serum tijdens therapie, als routine, wordt 
daarom door ons niet aangeraden. Een bijzondere bevinding was 
dat de serum goudspiegels van de met auranofin behandelde pa-
tienten op de lange duur bleken te dalen, ondanks constante 
dosering. Deze daling was "statistisch significant" na één 
jaar behandeling. Hoe dit moet worden verklaard is niet zeker; 
misschien is de verdeling van goud over de Ы o e d b e s t a n d d e l e n 
anders in het bloed van patiënten bij wie de therapie gunstig 
verloopt (meer goud aan bloedcellen, minder in serum). 
In hoofdstuk 8 worden verschillende methodes vergeleken om 
de hoeveelheid goud gebonden aan de rode bloedlichaampjes te 
meten. Er bleek een goede correlatie te bestaan tussen de ver-
schillende methoden. De conclusie was: de hoeveelheid cel-ge-
bonden goud kan betrouwbaar berekend worden uit de serumconcen-
tratie en de concentratie in het volledige bloed; het bewer-
kelijke meten van de goudconcentratie aan/in de bloedcellen 
apart is dus niet nodig. In onze beperkte gegevens vonden wij 
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géén opvallende relatie tussen het hebben van een ernstige 
nevenwerking vanaurothioglucose en de mate van goudbinding 
aan rode bloedcellen. 
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Stellingen 
behorende bij het proefschrift van 
P.L.C.M. VAN RIEL 
I 
Het gunstig reageren op aurothioglucose-injecties, bij patiënten met een reumatoïde 
arthritis, wordt deels door erfelijke factoren bepaald. 
Dit proefschrift 
II 
Reumatoïde arthritis patiënten met een van meet af aan, of later tot stand ge-
komen, verlaagd serum Ig A-gehalte hebben een grotere kans op het krijgen van een 
bijwerking van de aurothioglucose-behandeling dan patiënten met een verhoogd 
serum Ig A-gehalte. 
Dit proefschrift 
III 
De meest voorkomende bijwerking van auranofin, brijige ontlasting, is het gevolg 
van een direct toxisch effect van het orale goudpreparaat op de darmmucosa. 
Dit proefschrift 
IV 
Het meten van serum- of plasmagoudconcentraties tijdens behandeling met paren-
teraal toegediende goudpreparaten heeft géén therapeutische consequentie. 
Dit proefschrift 
V 
Een ernstige bijwerking van de aurothioglucose-behandeling gaat niet altijd gepaard 
met een gunstige therapeutische reactie. 
Dit proefschrift 
VI 
Hoewel het spreekwoord 'De ochtenstond heeft goud in de mond' letterlijk op de 
helft van de bestudeerde patiënten van toepassing was, gold de uitspraak 'Eind goed 
al goed' toch meer voor de andere helft van de groep patiënten. 
Dit proefschrift 
VII 
Het belang van een optimale farmacotherapie van de nederLmdse reumapatient is 
gediend met een goed functionerend 'Centrum voor klimsch-farmacologisch onder-
zoek van antireumatica' 
VIII 
Het beoordelen van de kwaliteit van een hoogleraar op basis van citatie-analyse via 
de naam van de eerste schrijver is onjuist, die hoogleraren die hun promovendi het 
eerste auteursschap gunnen worden hierdoor sterk benadeeld 
IX 
Het benoxaprofen 'schandaal' mag reden 7ijn te stellen dat farmacokinetisch 
onderzoek voor registratie óok, zo men wil juist, bij de groep van oudere patiënten 
en bejaarden verricht dient te worden 
X 
Dat een nieuwe behandeling iemand zal schaden staat vast, pas na een gedegen 
gecontroleerde studie wordt het duidelijk of er ook voldoende icmandcn genoeg 
baat bij hebben 
XI 
De tijd lijkt rijp om nieuwe geneesmiddelen alleen via het 'monitored relcase'-
systeem toe te laten voor registratie 
XII 
Hel is van belang bij een patient met een crosieve, seroncgatieve, met purulente, 
oligo- of polyarthritis te blijven zoeken naar een oorzakelijk agens 
Sacre А С , Grodzicki R L , Kornblatt Λ N et al , The spirochetal etiology of 
lyme disease Ν I ngl J Med 308 733 1983 
Grahamc R , Armstrong R , Simmons N et al , Chronic arthritis associated 
with the presence oj intras\novial rubella virus Ann Rheum Dis 42 2, 
1983 
XIII 
Len gouden toekomst mag slechts dan aan de croissanterieen hier te lande beloofd 
worden, indien de nedcrlandcr van overheidswege gedwongen wordt zijn vakantie 
binnen de eigen landsgrenzen door te brengen 
Nijmegen, 27 mei 1983 
Ρ LCM van Riel 


